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ABSTRACT 
Pulmonary fibrosis is the collective name for disorders characterized by excessive 
deposition of interstitial collagen in the lung.  Although the molecular mechanisms underlying 
pulmonary fibrosis are poorly understood, current evidence implicates both oxidant/antioxidant 
and protease/antiprotease imbalances in disease development.  Extracellular superoxide 
dismutase (EC-SOD) is an antioxidant enzyme protective against the development of 
pulmonary fibrosis in experimental models.  EC-SOD localization in the lung is regulated by a 
heparin-binding domain conferring affinity for the extracellular matrix.  This domain is 
susceptible to proteolytic removal, allowing EC-SOD to diffuse from the matrix.  While the in 
vivo protease of EC-SOD has not been identified, it is known that members of the matrix 
metalloproteinase  (MMP) family of proteases are upregulated in pulmonary fibrosis and could 
contribute to EC-SOD diffusion from the matrix.  Furthermore, latent MMPs can be activated by 
oxidants, indicating that loss of EC-SOD from the matrix could lead to increased MMP activity.   
It was hypothesized that the depletion of EC-SOD from the lung and interrelated increase 
in MMP activity contribute to pulmonary fibrosis development.  To examine this hypothesis, a 
mouse model of pulmonary fibrosis initiated by asbestos fibers (asbestosis) was developed.  This 
injury caused depletion of EC-SOD from the lung parenchyma.  Simultaneously, EC-SOD 
 iv
accumulated in the airspaces entirely due to release from airspace inflammatory cells.  Depletion 
from lung matrices may be important since EC-SOD knockout mice develop worse inflammation 
and fibrosis after asbestos exposure.   
The metalloproteinases, MMP-2 and MMP-9, were upregulated after asbestos exposure.  
MMPs appeared to be important in asbestosis development, as global pharmacologic inhibition 
of MMPs decreased disease severity.  MMP inhibition also reduced airspace EC-SOD 
accumulation, indicating a role for MMPs in EC-SOD localization.  EC-SOD knockout mice 
treated with asbestos did not have significantly different MMP-2 and -9 activity compared to 
wild type mice.  However, in bleomycin injury, knockout mice had increased airspace MMP-9, 
indicating a role for EC-SOD in the regulation of this protease.  In summary, our data provides 
strong evidence for contributory roles for both EC-SOD and MMPs in the development of 
pulmonary fibrosis and additionally provides novel insights into EC-SOD regulation in the lung. 
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1. INTRODUCTION 
 
Pulmonary fibrosis is the collective name for a group of disorders characterized by deposition of 
excessive amounts of collagen in the lung.  Pulmonary fibrosis can occur spontaneously without 
a known stimulus (idiopathic), in response to environmental and occupational exposures 
(asbestosis, silicosis), in response to drugs (bleomycin) and radiation, secondary to other diseases 
(scleroderma), and as a familial syndrome (1-6).  These diseases are extremely debilitating, 
leading to severe restrictive pulmonary impairment, as well as intractable, as no therapies exist to 
adequately treat the majority of patients (1).  Failure of current treatment regimens is largely 
owed to a general lack of understanding of the molecular mechanisms underlying pulmonary 
fibrosis.  However, current evidence points to both oxidant/antioxidant and protease/antiprotease 
imbalances as having central roles in these diseases. 
 
1.1. IDIOPATHIC PULMONARY FIBROSIS 
Idiopathic pulmonary fibrosis (IPF) is the paradigm fibrotic lung disease.  It is, by far, the most 
common of these diseases, accounting for 47-71% of all pulmonary fibrosis cases (7).  
Cryptogenic fibrosing alveolitis and idiopathic interstitial pneumonia are two other terms for IPF 
used outside of the United States (8).  The estimated prevalence of IPF is 29 per 100,000 in the 
general population (9). 
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1.1.1. Pathophysiology 
The primary function of the lung is to exchange gases between the bloodstream and the air we 
breathe.  Specifically, oxygen is transferred to hemoglobin in the blood while carbon dioxide is 
released from the hemoglobin to the airspace for exhalation.  Breathed air travels along a number 
of progressively narrowing conducting airways (trachea, bronchi, bronchioles) before reaching 
the respiratory bronchioles and alveoli where gas exchange actually occurs.  Crucial to gas 
exchange is the cellular design of the lung with type I epithelial cells facing the airspace sharing 
a common basement membrane with vascular endothelial cells facing the blood.  This barrier is 
exceedingly thin (as thin as 3.0 µm), allowing gas exchange to occur efficiently (10).  Support 
cells include the type II epithelial cells, which are poised to regenerate damaged type I cells and 
serve as a stem cell for the lung epithelium, and the Clara cell, which together with type II cells 
produces much of the surfactant vital to normal alveoli function.  Alveolar macrophages are also 
present and function in immunological defense (11). 
The lung in IPF is markedly different.  Interstitial collagen deposition leads to an inability 
of the lung to expand fully, thus decreasing total lung volume.  This defect has led to the 
classification of IPF as a restrictive disease (1).  In addition, thickening of alveolar septa 
increases the diffusion distance for gas exchange between the airspace and bloodstream.  This 
twofold effect on the reduction of lung volume and increased diffusion distance severely impairs 
normal respiration.   
The onset of IPF is usually insidious, with the first symptoms being nonproductive cough 
and shortness of breath (dyspnea) upon exertion.  The disease generally progresses to dyspnea at 
rest and eventually to the hypoxemia and respiratory failure that is the cause of death in most 
2 
patients (12).  IPF is a disease associated with aging as the peak incidence occurs after age fifty 
(1). 
Cardiovascular complications also cause mortality in IPF, accounting for 27% of deaths.   
Pulmonary hypertension and subsequent cardiac hypertrophy can result from blockage or 
constriction of pulmonary blood vessels.  The chronic hypoxemia in late stages of the disease is 
incapacitating and promotes stroke as well as heart ischemia and heart failure (12).  Overall 
prognosis in IPF is dismal; mean survival after onset of symptoms is 2.8-3.6 years (7, 13).   
 
1.1.2. Pathologic Findings 
IPF is defined histologically by a pattern of usual interstitial pneumonia (UIP).  The UIP pattern 
is that of patchy interstitial fibrosis appearing alongside normal lung.  Fibrosis is often found in 
subpleural and basilar areas and is temporally heterogeneous, that is, in various stages of 
development at the same time.  Fibroblastic foci composed of loose fibrosis populated by 
myofibroblasts (see Chapter 1.4.2) are scattered at the edges of this fibrosis.  Moderate 
inflammation may be present and is comprised of lymphocytes, macrophages, neutrophils, mast 
cells, and eosinophils (14). 
 Grossly, the lungs from an IPF patient are small.  The pleural surface has a “cobble-
stoned” appearance due to scar retraction.  Fibrosis is usually distributed in the lower lobes of the 
lung and in subpleural areas, with end-stage disease described as having honeycomb changes 
(14).  Bronchoalveolar lavage shows increases in the same inflammatory cells noted above (1).   
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1.1.3. Treatment 
Therapies for IPF are limited.  Front-line treatment has relied on corticosteroids and have a 
limited success rate, leading to a response in only 10 to 30% of patients (7).  Moreover, this 
treatment is limited by disabling side effects such as opportunistic infection, endocrine 
dysfunction, myopathy, and osteoporosis (1).  Although additional immunosuppressive drugs are 
often added to this regimen, treatment with cyclophosphamide has shown little to no benefit (15) 
while azathioprine-treated patients had only modest improvement in lung function parameters 
and mortality (16).  Unfortunately, antifibrotic medications such as colchicine and penicillamine 
have also shown little benefit (17).       
 Newer therapies have been attempted in the treatment of IPF.  Interferon gamma-1b was 
recently tested in a large, multinational, placebo controlled trial.  Unfortunately, in spite of 
promising preliminary data, interferon therapy did not significantly affect survival, lung function, 
or quality of life (18).  Because of evidence indicating oxidative stress in IPF, therapies aimed at 
restoring oxidant/antioxidant imbalance are being tested (19).  N-acetylcysteine, which 
stimulates the synthesis of the antioxidant glutathione, did not significantly affect survival but 
was found to improve pulmonary function tests in IPF patients (20).   
 Clearly, novel therapies are required to treat pulmonary fibrosis.  Better understanding of 
the disease mechanisms is crucial in the development of these therapies. 
 
1.2. ASBESTOSIS 
Although IPF is the most common interstitial lung disease, fibrosis can also occur due to particle 
exposure.  In short, asbestosis is pulmonary fibrosis due to the inhalation of asbestos fibers.  
Asbestosis is classified as a pneumoconiosis, that is, a pulmonary disease caused by exposure to 
4 
environmental dusts (21).  While asbestosis is thought to occur through many of the same 
mechanisms as IPF, it is clear that asbestos fibers also have unique characteristics that contribute 
to pathogenesis and require separate study. 
   
1.2.1. Asbestos and Lung Disease 
Because of its unique physical properties, asbestos fibers have been utilized for thousands of 
years.  High tensile strength and heat resistance has led to its use in concrete mixtures, brakes, 
shipbuilding, and insulation. Inexpensive and readily available, asbestos is extremely valuable 
for commercial and industrial applications (22). 
 Asbestos is composed of naturally occurring silica-containing mineral fibers.  Fibers are 
divided into two groups: serpentine (curly fibers) and amphiboles (straight fibers) (23).  
Chrysotile asbestos is the only member of the serpentine group, and these fibers are curly and 
flexible.  On the other hand, the amphiboles, including crocidolite (blue asbestos), amosite, 
tremolite, and others, are straight and are not pliable (22).  In terms of health impact, amphiboles 
are thought to be more potent inducers of disease because of their greater tendency to accumulate 
in the lung, inefficient pulmonary clearance of these fibers, and better durability.  Although 
controversial, this “amphibole hypothesis” may explain why a greater amount of chrysotile is 
required to cause disease compared to amphiboles (24).  In fact, the true contribution of 
chrysotile asbestos to disease in humans is unclear as chrysotile is commonly contaminated with 
small amounts of tremolite asbestos (an amphibole) (2).   
As would be expected, the largest number of cases of asbestos-related lung disease occurs 
in those with occupational exposure to the fibers.  As such, miners and millers, cement workers, 
insulation workers, and shipyard workers have high risk of disease development (25).  Diseases 
5 
caused by asbestos include asbestosis, pleural plaques, bronchogenic carcinoma, and 
mesothelioma (23). 
 
1.2.2. Clinical and Pathologic Features of Asbestosis 
Clinical manifestations of asbestosis are very similar to those described for IPF above but are 
generally less severe and slower in progression.  As in IPF, patients experience shortness of 
breath and dry cough early in disease.   These symptoms progress to respiratory failure and, 
eventually, death of the patient.  Although both IPF and asbestosis are associated with lung 
cancer, asbestosis patients have much higher rates of lung cancer (21). 
 Asbestosis is also akin to IPF in pathologic features.  Gross features are identical to that 
described for IPF, but additionally there may be pleural plaques.  Histologic diagnosis requires 
observation of diffuse interstitial fibrosis and asbestos bodies in lung sections.  In other words, 
asbestosis is essentially the patchy UIP pattern accompanied by asbestos bodies (21).  Asbestos 
bodies are asbestos fibers that have become covered with iron, protein and polysaccharides and 
have a characteristic brown, dumbbell appearance microscopically.  This process is not well 
understood but is thought to involve the action of macrophages (26). 
 
1.3. EXPERIMENTAL MODELS OF PULMONARY FIBROSIS 
Several in vivo animal models have been employed to examine the pathogenesis of pulmonary 
fibrosis.  These models typically rely upon an initial injury stimulus that leads to abnormal repair 
and fibrosis in the lung.  Two models that have been utilized extensively are the bleomycin and 
asbestos models. 
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1.3.1. Bleomycin Model 
The bleomycin model is the most common experimental model of pulmonary fibrosis in use 
today.  Bleomycin is a cancer therapeutic used in the treatment of lymphomas and solid tumors.  
Its use in cancer therapy is limited by significant skin toxicity and pulmonary fibrosis (27).  
These side effects are likely due to the absence in these tissues of bleomycin hydrolase, which 
inactivates bleomycin in other organs of the body (3). 
 Pulmonary fibrosis after bleomycin proceeds with an initial inflammatory phase followed 
by the actual development of fibrosis.  The initial injury has been proposed to be oxidative in 
nature—bleomycin can bind both DNA and redox-active iron simultaneously.  The iron can 
cause oxidative stress (see Chapter 1.4.5) that creates strand breaks in the DNA and presumably 
cellular dysfunction.  Pulmonary inflammation comprised of neutrophils, macrophages, and 
lymphocytes develops during the first seven days and likely participates in pathogenesis, since 
therapies that reduce this inflammatory response are associated with reduced fibrosis (28, 29).  
Fibrosis can also begin to develop as early as day seven depending on the route of 
administration.  This model has been successfully applied in mice, rats, hamsters, and rabbits 
(30-33). 
   
1.3.2. Asbestos Model 
The asbestos model involves the intratracheal instillation or inhalation of mineral fibers into the 
lung.  Like the bleomycin model, asbestos induces an acute inflammatory response followed by 
fibrosis (34).  Typically, the inflammation is dominated by neutrophils, although macrophages 
are present and may play a pivotal role in disease progression (35, 36).  A number of asbestos 
fibers have been used, including crocidolite, amosite, and chrysotile (37-39).  As in humans, the 
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type may be important, as amphiboles are retained in the lung longer than chrysotile (34, 40).  
Fiber length also is an important factor, as short fibers (<2.5 µm) were found to induce minimal 
fibrosis while longer fibers induced significant fibrosis (38, 41).  Mice, rats, hamsters, and 
several other animals have been exposed to asbestos and developed fibrosis (35, 38, 42).  
 
1.3.3. Pneumonia Model  
While bacterial inhalation does not cause the development of pulmonary fibrosis, bacteria can be 
utilized to reproduce the airspace inflammation found in pulmonary fibrosis.  While the actual 
development of pneumonia disease in response to bacteria varies due to genetic differences 
between mouse strains, the term pneumonia (as opposed to bacterial clearance) will be used for 
simplicity.  Notably, both pulmonary fibrosis and pneumonia lead to the accumulation of large 
amounts of neutrophils in the airspaces (35, 43).  The pneumonia is not complicated by 
interstitial fibrosis and extracellular matrix remodeling, nor does it lead to significant amounts of 
interstitial inflammation.   
 
1.4. PATHOGENESIS OF PULMONARY FIBROSIS 
The mechanisms underlying the development of IPF and asbestosis are still being elucidated.  
While the role of inflammation in the initiation or progression of the disease is unclear, current 
models view pulmonary fibrosis as a result of dysregulated repair processes.  Key to this 
dysfunction is failure of reepithelialization, activation of fibroblasts and myofibroblasts, 
inflammation, matrix remodeling, and oxidative stress (44).  These mechanisms likely apply to 
both IPF and asbestosis.  For simplicity, the following review of pathogenesis will first describe 
8 
findings attributed to IPF and potentially all interstitial lung diseases.  A more specialized 
description of asbestos-induced lung damage follows.   
 
1.4.1. Alveolar Reepithelialization 
Inability to regenerate pulmonary epithelium appears to play a major role in the development of 
pulmonary fibrosis.  Damage to epithelia is thought to be an early step in disease.  Fas-ligand 
pathway-induced apoptotic cell death in epithelium is increased, perhaps due to the actions of 
angiotensin II or transforming growth factor-beta1 (TGF-β1) (45-47).  The epithelial mitogen 
and motogen, hepatocyte growth factor (HGF), is also upregulated in IPF, probably representing 
an attempt to restore the epithelial barrier (48).  In fact, administration of HGF in animal models 
of pulmonary fibrosis reduces development of fibrosis (49).  However, although type I cell 
hyperplasia has been observed in IPF, the stem-cell like type II cells display reduced 
proliferation and differentiation capacity (50).   
 The plasminogen system is also thought to be involved in restoration of the epithelial 
barrier.  As plasma diffuses through damaged alveolar epithelium, fibrin clots are deposited in 
the lung (51).  Optimal reepithelialization requires the clearance of fibrin.  This process begins 
with conversion of plasminogen to plasmin by either urokinase plasminogen activator (uPA) or 
tissue plasminogen activator (tPA).  Plasminogen activator inhibitors (PAIs) are capable of 
inhibiting both uPA and tPA (52). 
 Factors increasing overall plasmin activity reduce the severity of pulmonary fibrosis in 
experimental systems.  In bleomycin models, plasminogen deficiency and PAI-1 overexpression 
led to increased fibrosis (51, 53).  Deficiency of PAI-1  and overexpression of uPA prevented 
fibrosis (51, 54).  This data is corroborated in human studies as IPF patients have suppressed 
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fibrinolytic capability (55).  Interestingly, fibrinogen null mice were not protected from lung 
fibrosis, suggesting that plasmin has beneficial roles apart from degrading fibrin (56), perhaps 
through the activation of latent growth factors (57) or matrix metalloproteinases (58).  In fact, the 
protection due to deficiency of PAI in mice is at least partly due to increased levels and 
availability of HGF in the lung (59). 
Growth factors originating from epithelium likely contribute to pulmonary fibrosis.  TGF-
β1 is a profibrotic growth factor found to be upregulated in human IPF (60).  Furthermore, 
induction of TGF-β1 by alveolar epithelial cells led to the development of pulmonary fibrosis in 
mice (61).  TGF-β exerts its actions through signaling intermediates known as Smads.  In 
bleomycin mouse models, the profibrotic Smads (Smads 2, 3, and 4) are increased in the lung 
while the antifibrotic Smad 7 is decreased (62).  The profibrotic Smads have been linked to 
increased production of various collagen proteins as well as increased tissue inhibitor of 
metalloproteinase-1, which would lead to overall collagen deposition (63).  One of the reasons 
behind the IFN-γ clinical trials in IPF patients is the fact that IFN-γ increased Smad 7 to inhibit 
TGF-β signaling and collagen synthesis (64, 65). 
Other growth factors, cytokines, chemokines, and prostaglandins from epithelium have 
been implicated in pulmonary fibrosis.  Overexpression of TGF-α from epithelium induced lung 
fibrosis in mice (66).  Platelet-derived growth factor (PDGF) promotes fibroblast migration and 
growth and is increased in IPF epithelial cells (67).    Tumor necrosis factor-alpha (TNF-α) 
expressed under the lung epithelial promoter induced inflammation that eventually led to fibrosis 
(68).  On the other hand, prostaglandin E2, which has an inhibitory effect on fibroblasts, is 
downregulated in IPF (69). 
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1.4.2. Fibroblasts and Myofibroblasts 
As the primary matrix-secreting cells in pulmonary fibrosis, fibroblasts and myofibroblasts play 
a key role in this disease.  Although fibroblasts are normally recruited after injury, repair in 
pulmonary fibrosis is abnormal, leading to excessive fibroblast activity (44).  Fibroblastic foci, 
composed of loose fibrosis populated with myofibroblasts, are a major focus of current research.  
These foci may represent the leading edge of fibrotic damage (70).   
 Proliferation of fibroblasts from IPF lungs can be either upregulated or downregulated, 
but downregulation is characteristic of advanced fibrosis and suggests more advanced 
differentiation (71).  IPF fibroblasts also display anchorage independent growth in vitro (72) and 
lower apoptosis rates (73).   Consistent with the disease process, IPF fibroblasts exhibit increased 
ECM production (74) and decreased capacity to degrade ECM due to increased tissue inhibitor 
of metalloproteinases (75, 76).   
 Fibroblasts can undergo conversion into myofibroblasts that possess an activated 
phenotype.  The myofibroblast has features of both fibroblasts and smooth muscle cells, 
producing large amounts of ECM protein (77) and possessing a contractile phenotype (78).  
Myofibroblasts are also capable of producing growth factors (79), cytokines (80), chemokines 
(81), and reactive oxygen species (82, 83). 
 
1.4.3. Inflammation 
The role of inflammation in pulmonary fibrosis is controversial.  A contributory role was 
previously assumed because of increases in leukocytes in BAL and histology sections in IPF.  
This inflammation is typically comprised of PMN, macrophages, eosinophils, mast cells, and 
lymphocytes (14).  These cells are capable of releasing large amounts of oxidants, proteases, 
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growth factors, and cytokines that can damage or induce damage in the lung.  The animal models 
of pulmonary fibrosis, including asbestos and bleomycin, support this concept, as fibrosis is 
generally preceded by inflammation (27, 35). 
 However, the causative nature of these changes has not been definitively proven in 
human disease.  Corticosteroids are potent anti-inflammatory agents but their efficacy in 
improving survival and pulmonary function as front-line therapies in IPF is low.  Levels of 
inflammation do not correlate with disease severity or outcome (84).  Selman and colleagues 
point out that some renal and liver fibrotic diseases occur in the presence of very low levels of 
inflammation (7).  In fact, one mouse model of IPF utilizing the overexpression of TGF-α 
demonstrated that development of fibrosis can occur in the absence of inflammation (66).  
Further, studies of epithelium and fibroblasts described above have demonstrated that these cells 
can produce the necessary factors to create a profibrotic environment and that inflammation may 
not be necessary.  In light of this evidence, many investigators are beginning to view IPF as a 
disease of abnormal chronic wound repair instead of fibrosis due to unrelenting inflammation.  
 
1.4.4. Matrix Turnover 
Clearly, a disorder involving deposition of excess collagen must involve imbalances in matrix 
formation and degradation.  In this regard, the matrix metalloproteinases and their inhibitors may 
play pivotal roles in the development of pulmonary fibrosis.  Indeed, abnormal expression and 
activity of the metalloproteinases have been reported in IPF.  These studies are discussed in more 
detail in Chapter 1.6.   
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1.4.5. Oxidative Stress 
A number of studies are uncovering a role for oxidative stress in the development of pulmonary 
fibrosis.  Oxidative stress refers to an imbalance in reactive oxygen species and antioxidants in 
which reactive oxygen species chemically modify biological molecules, potentially alterating 
their normal function.  Lungs in IPF patients are exposed to a greater oxidative burden than lungs 
from normal individuals (19, 85), thus suggesting a role for oxidative stress in this disease. 
 
1.4.5.1. Reactive Oxygen Species 
 
Molecular oxygen is abundant in the atmosphere and vital to life.  Oxygen is normally utilized as 
the terminal electron acceptor in the mitochondrial transport chain.  In a reaction catalyzed by 
cytochrome c oxidase in the inner mitochondrial membrane, oxygen undergoes a four-electron 
reduction to water (86).  However, oxygen can also undergo this reduction in an uncontrolled 
manner, leading to the production of potentially harmful chemical species.  
 Reactive oxygen species (ROS) are metabolites of oxygen that, in contrast to the parent 
molecule, have a propensity for participating in chemical reactions.  When oxygen undergoes 
sequential one-electron reductions, superoxide (O2·
-), hydrogen peroxide (H2O2), and hydroxyl 
radical (·OH) (which are all ROS) are formed before conversion to water (86): 
                                  e-                   e-                     e-                  e-
  O2    ?    O2·-    ?    H2O2   ?   ·OH   ?   H20   
                                                     + 2H+             - OH-            + H+
 
Superoxide and hydroxyl radical are free radicals, while hydrogen peroxide is not.  These 
metabolites can also lead to the production of other ROS.  Peroxynitrite, a potent ROS, is 
produced by a reaction between superoxide and nitric oxide (see Chapter 1.4.5.2) (87) and a 
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reaction between hydrogen peroxide and nitrite (88).   ROS can be formed in any cell that 
utilizes mitochondrial respiration or is exposed to oxygen, an idea confirmed by the ubiquitous 
presence of antioxidants.  Most cells can also produce ROS in a concerted fashion through 
enzymes such as NADPH oxidases and xanthine oxidase (89, 90).  Cells capable of especially 
high production of ROS include inflammatory cells and myofibroblasts.   
ROS can cause chemical modifications in DNA (e.g. strand breaks, mutations), lipids 
(thromboxane formation, lipid peroxidation), proteins (altering function, often at sulfhydryl 
groups; protein fragmentation), and transcription factors (91, 92).  Such modifications can 
seriously impair the biological functions of these molecules.  In the chemical reactions, the ROS 
typically gain electrons and therefore act as oxidizing agents or oxidants.  ROS are opposed by 
antioxidants, which remove ROS before they can cause damage to cells and tissues.  Oxidative 
stress occurs when there is an imbalance favoring oxidants over antioxidants.  Oxidative stress 
has been reported to play a role in cardiovascular disease (93, 94), neurodegeneration (95), 
cancer (96-98), and aging (99). 
 
1.4.5.2. Superoxide 
 
The superoxide radical anion (O2·
-) is the result of a one-electron reduction of molecular oxygen.  
Superoxide is always produced during the normal reduction of oxygen to water, but 
intracellularly, superoxide can also be formed in mitochondria by the reaction of oxygen with 
electrons leaked from the electron transport chain.  Neutrophils, monocytes, and macrophages, 
among other cells, can also produce superoxide using NADPH oxidase (86).  As part of host 
defense, neutrophils harness this superoxide to produce hypochlorous acid (HOCl, bleach) 
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through the myeloperoxidase enzyme.  These reactions by inflammatory cells are known as the 
oxidative burst and can inflict major damage to invading pathogens as well as normal tissue (86).   
 Despite being a free radical, superoxide is relatively unreactive and is actually better at 
donating electrons (acting as a reductant) than accepting them (acting as an oxidant).  Superoxide 
can nonetheless participate in reactions that produce potent oxidants (100).  One such reaction is 
spontaneous dismutation in which superoxide acts as both an oxidizing and reducing agent in the 
same reaction.  This leads to the production of hydrogen peroxide and oxygen: 
  2 O2·
-    +    2H+   ?   H2O2    +    O2
This reaction can also be catalyzed by antioxidant enzymes known as superoxide dismutases (see 
Chapter 1.5).   
 Superoxide can also participate in hydroxyl radical formation.  Superoxide can react with 
nitric oxide (NO) at a rate of 109 to 1010 per mole per second to form the powerful oxidizer 
peroxynitrite (ONOO-) (101).  Peroxynitrite can mediate major modifications of biological 
molecules, such as the formation of nitrotyrosine modifications at tyrosine residues in proteins 
(87).  Peroxynitrite also decomposes at physiological pH to form hydroxyl radical and nitrogen 
dioxide: 
 
  O2·
-   +   NO·    ?     ONOO -    
  ONOO -   +   H+    ?    ONOOH  
ONOOH      ?   ·OH   +   NO2· 
 
Peroxynitrite, the hydroxyl radical, and nitrogen dioxide are all potent oxidants thought to be 
important in a number of diseases, including pulmonary fibrosis (102, 103).  Since there is 
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increased nitric oxide production in pulmonary fibrosis (103, 104), this pathway may be of 
particular importance in this disease. 
 Superoxide can also produce hydroxyl radical though the Haber-Weiss reaction, in which 
ferric iron (Fe3+) is reduced to ferrous iron (Fe2+) by superoxide (105).  Ferrous iron then reacts 
with hydrogen peroxide to form the hydroxyl radical: 
  O2·
-    +    Fe3+   ?   Fe2+    +   O2
  H2O2   +   Fe2+   ?  ·OH   +   OH-   +   Fe3+
Therefore, iron undergoes oxidation/reduction (redox) as a catalyst for this reaction.  The second 
reaction by itself is also known as the Fenton reaction.  Since availability of free ferric and 
ferrous iron is limited in the body, the physiological importance of this reaction may be limited 
to cases in which exogenous iron is present.  Notably, the ability of asbestos fibers to bind metal 
ions could provide a source of redox-available iron for this reaction (see Chapter 1.4.6).   
 
1.4.5.3. Nitrosative Stress 
 
Nitric oxide (NO·) is capable of forming powerful oxidants, and these species can modify and 
alter the functions of proteins.  Nitrosative stress occurs in disease states in which excess reactive 
nitrogen species (RNS) leads to undesirable modifications of biological molecules.  Nitric oxide 
is produced by nitric oxide synthases (NOS) from L-arginine and oxygen.  Two NOS enzymes 
are constitutively expressed and produce nitric oxide at low levels under normal conditions.  The 
inducible form of these enzymes (iNOS), can produce up to 20 times more nitric oxide and is 
upregulated in response to stimuli such as lipopolysaccharide (87).   
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 As noted above, peroxynitrite is produced by the rapid reaction between superoxide and 
nitric oxide.  Production of this powerful oxidant is probably a defense against microorganisms, 
as evidenced by the fact that salmonella have evolved peroxynitrite reductase enzymes to cope 
with its release (106).  Peroxynitrite can oxidize thiols and modify tyrosines on proteins.  Such 
modifications can seriously alter protein function, which has been described in Alzheimer’s 
Disease and ulcerative colitis of the gut, among other diseases (107, 108).  Nitric oxide also has a 
potential role in cell signaling, as it inhibits the phosphorylation of the inhibitor of NF-κΒ (109).   
  
1.4.5.4. The Lung’s Antioxidant Defenses 
 
The lung may be especially vulnerable to ROS as it is exposed to higher oxygen tensions than 
other vital organs.  Furthermore, cigarette smoke and other environmental pollutants represent 
additional oxidant burdens for the lung.  These exposures necessitate strong antioxidant defenses 
to prevent excessive damage to the lung (110).   
 Various antioxidants with specialized functions are present in the lung to scavenge the 
different ROS.  Glutathione may be the most important bulk scavenger of hydrogen peroxide in 
the lung and is 140 times more abundant in lung epithelial lining fluid compared to blood (111).  
Reduced gluatathione (GSH) is utilized by glutathione peroxidase enzymes to reduce hydrogen 
peroxide to water.  Hydrogen peroxide is also removed by catalase, which enzymatically 
catalyzes its reduction to water (86).  The superoxide dismutases (see Chapter 1.5) are a major 
group of three antioxidants that collectively scavenge superoxide intracellularly and 
extracellularly (112).  Vitamins, mucins, metal-binding proteins, and albumin also have potential 
antioxidant functions in the lung (19, 86). 
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1.4.5.5. Oxidative Stress in IPF 
 
Current evidence indicates that IPF lungs are exposed to especially high oxidant burdens.  
Bronchoalveolar lavage (BAL) fluid from IPF patients possessed increased oxidative stress 
markers including lipid peroxidation (85) and 8-isoprostane (113).    IPF lungs contain more 
myeloperoxidase (114), while inflammatory cells from IPF patients release more superoxide and 
hydrogen peroxide than normal (115, 116).   
 Abnormal nitric oxide regulation has also been observed in IPF.  Saleh and colleagues 
found increased nitrotyrosine in IPF lungs, indicating peroxynitrite-mediated modifications 
(103).  This study and others  also found increases in iNOS in early to intermediate stage IPF 
localizing to macrophages, neutrophils, and alveolar epithelium (117).  However, iNOS 
expression was significantly decreased in end-stage samples, suggesting a role only in early and 
intermediate disease (103).   
 Numerous studies in human IPF lung samples have described abnormal antioxidant 
levels.  A number of investigations have observed decreased reduced (protective) glutathione in 
both alveolar lining fluid (85) and intracellularly (118).  Although catalase exhibited no major 
changes, manganese superoxide dismutase (MnSOD) is markedly upregulated in UIP lungs 
compared to normal lung.  While this may represent a compensatory response against increased 
oxidants, MnSOD levels were found to be low in mature fibrosis, suggesting a deficiency in 
antioxidant protection late in IPF (119).   
 While the above studies in human IPF are invaluable, ROS and RNS have also been 
implicated in experimental models of pulmonary fibrosis.  In bleomycin-induced pulmonary 
fibrosis in mice, superoxide dismutase activity was protective against disease development 
(discussed in more detail in Chapter 1.5.5).  Experimental therapies with agents possessing 
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antioxidant capability reduced fibrosis development (120-124).  Reduction in mortality, 
inflammation, and lipid peroxidation were noted.  NOS inhibition also reduced fibrosis without 
affecting inflammation in one study, (125).  However, inflammation was increased in iNOS null 
mice in a conflicting study (126). 
 The potential targets of increased oxidative stress in IPF are numerous.  It has been 
proposed that ROS can interact with proteases and their inhibitors to alter their function in the 
lung (127).  The matrix metalloproteinases (see Chapter 1.6) represent an entire family of 
proteolytic enzymes that can be activated by ROS through oxidative modification of the cysteine 
switch (128).  In addition, protease inhibitors such as tissue inhibitors of metalloproteinases 
(129), alpha-2-macroglobulin (130), and secretory leukocyte protease inhibitor (131) can be 
inactivated by oxidative stress.  The inactivation of alpha-1-proteinase inhibitor (α1-PI) by 
cigarette smoke ROS is pathogenic in the development of emphysema (132, 133).  Notably, α1-
PI deficiency was described in familial IPF (134).  Smokers have higher rates of IPF, which may 
be explained through inactivation of α1-PI by ROS (135). 
 TGF-β is a potent profibrotic growth factor and can be modulated by ROS.  ROS can 
release this growth factor from lung epithelium (136) and cause its activation through 
dissociation from latency associated peptide (137).  Active TGF-β can in turn induce 
myofibroblasts to produce more ROS in a positive feedback loop (83). 
 Transcription factors are sensitive to oxidative stress.  The Nrf2 transcription factor is 
redox sensitive and is responsible for the upregulation of a number of antioxidants, including 
glutathione peroxidase (138).  NF-κB is also sensitive to redox modulation, and its activity is 
abrogated in NAC-treated animal models (139). 
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Based on the evidence above, antioxidant therapies were designed to treat patients with IPF.  
Trials involving N-acetylcysteine (NAC) have been encouraging.  NAC is a source of cysteine, 
the precursor for glutathione synthesis.  NAC therapy increased both intracellular glutathione in 
BAL fluid cells and extracellular glutathione in the BAL fluid itself (20, 118, 140).  IPF patients 
on this therapy exhibited improved pulmonary function tests and blood oxygen saturation 
compared to pre-therapy (20).  A large European trial is confirming these results with NAC 
(141). 
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Figure 1.  Overview of the role of oxidative stress in pulmonary fibrosis. 
Exogenous and endogenous irritants in IPF create a redox imbalance resulting in the production of reactive 
oxygen species (ROS).  Widespread effects on epithelium, myofibroblasts, growth factors (e.g. TGF-β), 
inflammatory cells, proteases (e.g. MMPs), protease inhibitors, and the extracellular matrix (ECM) may 
ultimately contribute to the development of end stage fibrosis.  Shown also are endogenous antioxidants 
(green boxes) and the steps at which they can protect the lungs from the effects of ROS.  Processes outside the 
cell, such as the activation of TGF-β and MMPs, would be primarily affected by the major extracellular 
antioxidants including GSH, EC-SOD, and small molecules such as vitamins.  Exogenous antioxidants such as 
N-acetylcysteine (NAC) and superoxide dismutase (SOD) mimetics can augment antioxidant defenses and 
thus serve as potential therapies for IPF.  Definition of abbreviations:  GSH = glutathione; GPx = glutathione 
peroxidase; eGPx = extracellular glutathione peroxidase; HO-1 = heme oxygenase-1; CuZnSOD = 
copper/zinc superoxide dismutase; MnSOD = manganese superoxide dismutase; ECSOD = extracellular 
superoxide dismutase; α1PI = alpha-1-proteinase inhibitionr; α2M = alpha-2-macroglobulin; TIMP = tissue 
inhibitior of metalloproteinases. 
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1.4.6. Pathogenesis of asbestosis 
The pathogenesis of asbestosis is thought to involve many of the same mechanisms described 
above for IPF, which is not surprising considering the similarities between the diseases clinically 
and pathologically.  Growth factors, cytokines, inflammation, oxidative stress, apoptosis, and 
signaling are all thought to contribute to asbestosis pathogenesis.   
Various growth factors and cytokines are increased in asbestos-mediated injury.  A 
number of studies have noted an upregulation of the profibrotic TGF-β after asbestos exposure 
(142-144).  Asbestos-induced increases in fibroblast growth factor (145), and in PDGF (146) and 
its receptor (147) have also been described.   
Inflammation appears to play a more definite pathogenic role in the development of 
asbestosis than in IPF.  In humans with asbestosis and in animal models of this disease, BAL 
fluid contains increased macrophages and neutrophils (38, 148, 149).  Asbestos-exposed 
endothelial cell cultures upregulate ICAM-1 which increases neutrophil adherence, an important 
step in diapedesis into lung tissue (150).  The chemoattractants, macrophage inflammatory 
protein (MIP) and interleukin-8, and proinflammatory cytokines, TNF-α and IL-1, were all 
upregulated in response to asbestos (151-154).  As phagocytic inflammatory cells unsuccessfully 
attempt to engulf asbestos, a process that has been termed “frustrated phagocytosis,” these cells 
produce ROS (155, 156). 
 
1.4.6.1. Role of oxidative and nitrosative stress. 
 
Perhaps even more than in IPF pathogenesis, ROS and RNS are hypothesized to play a major 
role in the development of asbestos-related diseases.  The reason for this emphasis is twofold.  
First, the iron present on asbestos fibers can, at least theoretically, catalyze the Haber-Weiss 
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reaction to produce potent oxidants such as the hydroxyl radical.  Thus, many studies focus on 
iron-loading or iron chelation of asbestos fibers as a method by which to modulate ROS 
production in model systems.  Second, the inflammatory cells that populate the lung in asbestosis 
are potent producers of oxidants and can add significantly to the oxidant burden in the lung.  
 A large body of literature provides support for the free radical hypothesis of asbestos 
injury.  Investigators have detected the in vivo formation of both lipid peroxidation products and 
hydroxyl radicals after intratracheal administration of asbestos in rats (157, 158).  The source of 
this ROS may be inflammation, as exposure of macrophages to asbestos leads to increased 
production of hydrogen peroxide, superoxide, and both inducible NOS and nitric oxide (35, 156, 
159, 160).  Lungs from rats treated with asbestos increase production of CuZnSOD, MnSOD, 
catalase, and glutathione peroxidase, likely as a compensatory increase in response to elevated 
oxidative stress (161).   
 Experimental evidence has also shed light on some of the targets of ROS in asbestosis.  
Through an iron-dependent mechanism, asbestos was shown to increase expression of PDGF-A, 
TGF-β1, and procollagen in rat tracheal explants.  The growth factor effects were dependent 
upon the extracellular signal-regulated protein kinase (ERK) pathway, while procollagen was 
governed by NF-κB (146), both of which are redox sensitive (162).  Asbestos also causes DNA 
strand breaks, an event associated with ROS and which in this study correlated with hydroxyl 
radical formation, also in an iron-dependent manner (163).  Nitric oxide was found to be 
involved in the oxidation of DNA in human epithelium, as measured by levels of 8-hydroxy-2-
deoxyguanosine (164).  In alveolar epithelial cultures, asbestos induced mitochondrial 
dysfunction (37) and caspase-3 activation leading to apoptosis that was attenuated by iron 
chelation and hydroxyl radical scavengers (165).   
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 Experimental studies have described conflicting results regarding superoxide dismutase 
involvement in the disease.  MnSOD overexpression protected epithelium from asbestos-
mediated cytotoxicity (166).  Macrophages were also protected from cytotoxicity by superoxide 
dismutase and catalase in vitro (160).  However, one investigation found no effect from osmotic 
pump treatment in rats with superoxide dismutase conjugated to polyethylene glycol to increase 
half-life.  This study did find a protective effect with similarly conjugated catalase (149).  These 
differences may be due, at least in part, to the localization of the SOD that is being added to the 
system.  MnSOD is intracellular while conjugated SOD is extracellular.  Furthermore, the 
conjugation to polyethylene glycol may prevent SOD from getting to the cell surface.  The role 
of SOD in asbestosis remains to be further elucidated. 
  
1.5. EXTRACELLULAR SUPEROXIDE DISMUTASE 
Extracellular superoxide dismutase (EC-SOD) is the third mammalian enzyme discovered that 
catalyzes the dismutation of the superoxide anion to hydrogen peroxide and oxygen.  Particularly 
abundant in the lung, a number of functions in the pulmonary architecture have been attributed to 
EC-SOD.  In particular, current evidence suggests that loss of EC-SOD plays a role in the 
development of interstitial lung disease.   
 
1.5.1. Historical Background 
The first discovery of superoxide dismutases (SODs) took place in 1969, when Joe McCord and 
Irwin Fridovich demonstrated superoxide dismutase activity for a previously described protein, 
erythrocuprein.  This protein came to be known as copper/zinc SOD (CuZnSOD, also known as 
SOD1) because of its metal content (167).  The authors noted that the existence of the enzyme 
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indicated a vital role in protection against the superoxide radical.  Manganese SOD (MnSOD, or 
SOD2) was discovered four years later by Weisiger and Fridovich in mitochondria, and unlike 
CuZnSOD was insensitive to cyanide (168).  It was not until 1982, thirteen years after the first 
discovery of SODs, that the third mammalian isozyme was purified from human lung by Stefan 
Marklund (169).   
 Extracellular superoxide dismutase (EC-SOD, or SOD3) had a much higher molecular 
weight than the other two SODs.  It was partially purified utilizing concanavalin A-sepharose, 
indicating the presence of N-linked carbohydrate moieties.  The enzyme eluted from a heparin-
sepharose column in three fractions, denoting varying affinity for heparin.  Like CuZnSOD, EC-
SOD was sensitive to cyanide (169).  
 
1.5.2. Biochemistry of EC-SOD 
EC-SOD (EC 1.15.1.1) is a 135kD, homotetrameric enzyme capable of catalyzing the 
dismutation of superoxide free radicals.  The complete enzyme is formed by two disulfide linked 
dimers (Figure 2).  The intersubunit disulfide bridges connect cysteines at the C-terminal end of 
each subunit (170).  Noncovalent interactions at the N-termini hold together the four subunits of 
the complete enzyme.  While both mouse and human EC-SOD share this overall structure, rat 
EC-SOD exists only as a dimer (171).  N-linked glycosylation at Asn89 (numbering according to 
the human protein) explains the affinity of EC-SOD to concanavalin A (172).  Each subunit 
contains one copper and one zinc atom (169). 
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Figure 2.  The EC-SOD homotetramer can have varying affinities for heparin. 
EC-SOD in mice and humans is composed of four identical subunits.  Two of the subunits form a disulfide-
linked dimer at the C-terminus while noncovalent interactions at the N-terminus hold the complete tetramer 
together.  Each subunit is synthesized with a heparin-binding domain near the C-terminus with the 
underlined sequence shown at the bottom of the figure (a Type C subunit).  The four heparin-binding 
domains can be sequentially cleaved by proteases (forming Type A subunits) after protein synthesis, leading 
to high, medium, and low affinity for heparin.    
 
 
 The C-terminal domain of EC-SOD is unique among SOD enzymes and plays a role in 
regulating tissue distribution.  Positions 210-215 in the enzyme are composed of six positively 
charged amino acids with the sequence Arg-Lys-Lys-Arg-Arg-Arg in both humans and mice.  
This sequence provides affinity for heparin and the extracellular matrix (173, 174).  A mutation 
in this sequence converting arginine at position 213 to glycine has been described in humans.  
This mutation significantly reduces the heparin affinity of EC-SOD, leading to a 10-fold increase 
in plasma EC-SOD and confirming the importance of this heparin-binding domain in EC-SOD’s 
matrix localization (175).  This mutation may play a role in cardiovascular health (see Section 
1.5.4). 
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The heparin-binding domain (HBD) can be posttranslationally cleaved from the enzyme, 
leading to a loss of heparin affinity.  The truncated EC-SOD has a sequence ending at Glu209 
and retains full enzymatic activity (172).  Since each subunit of EC-SOD has its own HBD, the 
tetrameric enzyme could have zero to four total HBDs, leading to EC-SOD with affinity for 
heparin that varies from none to strong.  Indeed, during heparin-sepharose purification of EC-
SOD, the enzyme was recovered in three fractions: type A (no affinity), type B (moderate 
affinity), and type C (strong affinity) (169, 173).  A number of proteases, including trypsin and 
plasmin, have been shown to cleave this domain in vitro (176).  Although furin has also been 
demonstrated to cleave this domain intracellularly in cell cultures (177, 178), the in vivo protease 
responsible for this cleavage in lung tissue, particularly in disease states, is currently unknown. 
Recently, a second structure of EC-SOD was described with a different pattern of 
intrachain disulfide bridges.  The newly discovered tertiary structure creates a more constrained 
structure that is enzymatically inactive.  This inactive EC-SOD is present in low abundance in 
humans but has not been found in any other species including the mouse.  The importance of this 
form of EC-SOD is currently being examined (179). 
The EC-SOD gene is approximately 5900 bp long, located on human chromosome 4 
(180, 181).  The promoter contains antioxidant and xenobiotic response elements, and AP-1 
binding sites (181).  Interferon-γ increases EC-SOD expression while TNF-α and TGF-β 
suppress it (182).   
 
1.5.3. Distribution of EC-SOD 
EC-SOD is present in many tissues and extracellular fluids.  The enzyme exists in particularly 
high concentrations in arteries and in pulmonary airways (183).  EC-SOD is also abundant in 
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lung alveoli of humans and mice where it is produced by type II epithelial cells, bronchial 
epithelial cells, macrophages, and neutrophils (184-186).  EC-SOD is also present in plasma, 
kidney, heart, brain, and the uterus (173, 175, 186, 187).    
 
1.5.4. Function of EC-SOD in tissues 
EC-SOD catalyzes the dismutation reaction of superoxide at a rate constant of 1 x 109 per 
mole per second, which is almost diffusion limited (169).  The enzyme thus produces oxygen 
and hydrogen peroxide, the latter detoxified through the action of catalase and peroxidases in 
cells and tissues.  More importantly, SOD removes superoxide from the system, eliminating a 
potential source of potent oxidants (see Chapter 1.4.5.2).  
EC-SOD has multiple roles in normal homeostasis.  Since superoxide can react with 
nitric oxide at diffusion limited rates, EC-SOD can preserve nitric oxide to allow vasorelaxation 
and other functions (172).  Scavenging of superoxide also prevents the formation of peroxynitrite 
and hydroxyl radical and decreases oxidant-mediated damage to tissues (112).  Since neutrophils 
produce large amounts of superoxide, EC-SOD may act to balance the large pro-oxidant 
activities of these inflammatory cells (184).  EC-SOD is also known to bind type I collagen and 
protect it from oxidative fragmentation, indicating an important role in protecting ECM 
components from oxidative stress (174). 
EC-SOD has been implicated in a number of diseases in a number of different organ 
systems in the body.  Atherosclerosis is thought to involve ROS, and patients with coronary 
artery disease have significantly reduced EC-SOD levels (188).  Even more impressive is an 
association found between persons with the Arg213Gly mutation of EC-SOD and ischemic heart 
disease.  In a large prospective study, Juul and colleagues found that persons with the mutation, 
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which leads to accelerated loss of EC-SOD from arterial walls, carry 1.5 times the risk of 
ischemic heart disease (189).  Experimentally, diabetic arteries contained less EC-SOD than 
nondiabetic controls (112), and EC-SOD protects against focal cerebral ischemia (190, 191).  
Ischemia/reperfusion injury was also reduced in experiments using recombinant EC-SOD (192).   
EC-SOD knockout mice have impaired learning and memory (193).  Controversy exists over the 
role of EC-SOD in rheumatoid arthritis, but its abundance in synovial fluids suggests that it 
could be protective (194).   
The presence of EC-SOD in alveoli, the primary site of damage in pulmonary fibrosis, 
implies a function in protecting the lung from oxidants (195).  Utilizing knockout and transgenic 
mice, EC-SOD was found to be protective in various animal models of lung disease, including 
hyperoxia in adult (196, 197) and newborn mice (198), lung damage from oil fly ash (199), 
hemorrhage-induced lung injury (200), and LPS-induced neutrophilic inflammation (201).  EC-
SOD is effectively able to inhibit the pulmonary inflammation common to these diseases.  This 
effect may be related to decreases in NF-κB activity (200) and to blocking ROS-mediated 
upregulation of vascular selectins and proinflammatory cytokines (MIP-2, TNF-α) important for 
neutrophil diapedesis and chemotaxis (201).   
 
1.5.5. EC-SOD in pulmonary fibrosis 
An increasing body of evidence supports a role for EC-SOD in the pathogenesis of pulmonary 
fibrosis.  In a bleomycin mouse model of pulmonary fibrosis, EC-SOD has been shown to have a 
protective effect.  Transgenic mice that express increased levels of EC-SOD are protected from 
development of pulmonary fibrosis (202).  Similarly, treating mice with exogenous SOD or SOD 
mimetics leads to decreased severity of bleomycin-induced disease (120, 203).  On the other 
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hand, EC-SOD knockouts develop more severe fibrosis after bleomycin.  In the knockout mice, 
this fibrosis is accompanied by increases in inflammation and an increase in oxidative 
fragmentation of collagen (204) which may propagate the inflammatory response as collagen 
fragments are known chemoattractants and activators of neutrophils (205, 206).  These studies 
indicate that EC-SOD plays a protective role against inflammation and pulmonary fibrosis. 
Notably, EC-SOD is depleted from the lung parenchyma of mice treated with bleomycin 
(207) or hyperoxia (208).  This depletion appeared to be due to the proteolytic cleavage of the 
heparin-binding domain of EC-SOD and was associated with accumulation of proteolyzed EC-
SOD in the airspaces presumed to originate from the lung parenchyma.  This study suggested 
increased susceptibility of the lung to oxidative stress in pulmonary fibrosis and hyperoxic 
interstitial lung injury through proteolytic removal of EC-SOD from lung parenchyma.  The in 
vivo protease responsible for this redistribution is currently unknown, but a number of proteases 
including the MMP family are known to be upregulated in IPF and hyperoxia which may 
contribute to this redistribution of EC-SOD.  
Collectively, the studies described above indicate important functions for EC-SOD in 
pulmonary fibrosis.  No studies of EC-SOD in human IPF have been reported in the literature.  
Importantly, EC-SOD has also never been examined in the context of pneumoconiosis diseases. 
 
1.6. MATRIX METALLOPROTEINASES 
The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes with the capability 
of degrading a wide variety of extracellular proteins.  The first discovery of these enzymes came 
in 1962, when Gross and Lapiere described collagenase activity in metamorphosing tadpoles 
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(209).  At least 25 MMPs are now known to exist and are attributed diverse roles described in 
normal tissue and disease (210).   
 
1.6.1. Biochemistry of Matrix Metalloproteinases 
The basic structure of MMPs involves a number of building blocks common to all members of 
this family.  These building blocks include a signal peptide, prodomain/propeptide, catalytic 
domain, and C-terminal hemopexin-like domain.  The signal peptide governs secretion from the 
cell, while the C-terminal domain plays a role in substrate specificity.  The catalytic domain is 
highly conserved among the MMPs, consisting of the sequence HEXGHXXGXXHS/T, in which 
the three histidines coordinate with an active site zinc atom.  The propeptide consists of a 
conserved cysteine in the sequence PRCXXPD that coordinates with the active site zinc and 
renders the enzyme inactive at time of synthesis.  Some MMPs possess unique domains in 
addition to those described above, such as GPI-linked transmembrane domains and fibronectin-
like repeats.  At the other extreme is MMP-7 (matrilysin), a “minimal” MMP that possesses only 
the signal domain, prodomain, and catalytic domains and lacks the hemopexin-like domain.   
MMPs have been grouped by their in vitro substrate specificity, although much debate 
surrounds their in vivo substrates.  A partial list of the MMPs and their substrates is shown in 
Table 1.  The collagenases are capable of cleaving collagen types I and II (211).  The gelatinases 
(MMP-2 and -9, also known as gelatinase A and B) are known for their ability to degrade not 
only gelatin (denatured collagen) but also native type IV collagen, the critical component to 
basement membranes.  However, diverse roles for the MMPs are being described, and structural 
ECM components are no longer the only recognized substrates for these enzymes.  
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Table 1.  Partial list of metalloproteinases implicated in pulmonary fibrosis and their substrates.  
MMP Other name Substrates Expressed in 
MMP-1 
MMP-8 
MMP-13 
Interstitial collagenase 
Neutrophil collagenase 
Rat collagenase 
Type I and II fibrillar  
   collagens (209, 211) 
Fibroblasts (212),  
inflammatory cells  
   (213) 
MMP-2 
MMP-9 
Gelatinase A 
Gelatinase B 
Native type IV  
   collagen (214),  
gelatins (215),  
α1-proteinase  
   inhibitor (MMP-9  
   only) (216) 
Fibroblasts (214),  
inflammatory  
   cells (213, 217),  
epithelium (218, 219) 
MMP-7 Matrilysin Syndecans (29),  
e-cadherin (220),  
FAS ligand (221),  
pro-alpha-defensins  
   (222), 
a1-proteinase 
inhibitor (223) 
Epithelium (224) 
  
 
As noted above, MMPs share a common mode of activation termed the “cysteine switch” 
whereby disruption of the active site cysteine-zinc bond leads to autocatalytic cleavage of the 
prodomain and activation of the latent enzyme.  However, this disruption can occur in a number 
of ways.  Proteolysis of the prodomain has been demonstrated by furin (225), plasmin (226), and 
other metalloproteinases (227) leading to activation of MMPs.  A well-described mode for MMP 
cross-activation is the cell surface activation of MMP-2 by the membrane anchored MT-MMP1 
through a mechanism requiring the MMP inhibitor, TIMP-2 (228).   
Modification of the cysteine switch by ROS or RNS can also activate MMPs.  
Hypochlorous acid oxidizes and activates MMP-7 (229). Hydrogen peroxide, peroxynitrite, and 
oxidants produced by the xanthine/xanthine oxidase system can activate both MMP-2 and MMP-
9 (230, 231).  The cysteine switch of MMP-9 can also be activated by nitric oxide through S-
nitrosylation of the thiol group (232)(29).  In addition, ROS have been shown to directly induce 
MMP transcription (233).  Importantly, ROS do not always activate proteases, but can inactivate 
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them as well.  Hypochlorous acid can inactivate gelatinases (234) and even MMP-7 (235), which 
it previously was shown to activate, at high concentrations.  Therefore, it is likely that local 
concentrations of ROS/RNS will determine whether MMPs are activated or inactivated. It has 
been suggested that the rapid activation and subsequent inactivation of MMPs by oxidative 
mechanisms could regulate powerful “quantum bursts” of proteolytic activity (210). 
Endogenous inhibitors serve to inactivate MMPs after prodomain cleavage.  Four tissue 
inhibitors of metalloproteinases (TIMPs) have been described.  TIMPs can bind MMPs with 1:1 
stoichiometry to inhibit their activity.  There is some specificity, as certain TIMPs preferentially 
bind some MMPs (236).  However, as described above, some TIMPs can play a role in activating 
MMPs (228).  Another general inhibitor of MMPs is alpha-2-macroglobulin (a2M).  This large 
inhibitor traps proteases and governs their removal from tissues and the circulation (237).   
Among the members of the MMP family, much research has focused on the roles of 
MMP-2, MMP-9, and MMP-7 in the development of IPF.  Increases in all three of these MMPs 
have been demonstrated in human IPF and in experimental models.  The exact function of these 
proteases in vivo in the lung requires further study.   
 
1.6.2. MMP-2 and MMP-9: the Gelatinases 
MMP-2, also known as gelatinase A or 72-kDa gelatinase, can be produced by both fibroblasts 
(212) and epithelium (218) in the lung.  MMP-2 possesses a fibronectin-like domain that likely 
mediates binding to gelatins (238).  MMP-2 proteolytically cleaves gelatin (239), type IV 
collagen (240), and elastin (241).  TGF-β is capable of upregulating MMP-2 in fibroblasts (212).  
The enzyme can be activated by MT-MMP-1 (228), urokinase, and plasmin (242).  ROS can also 
activate MMP-2 as described above.   
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MMP-9, also known as gelatinase B or 92-kDa gelatinase, is produced by neutrophils 
(243, 244), macrophages (245), T cells (246), and some fibroblasts (247).  While normal lung 
does not produce much MMP-9, the following cells can be induced to produce it:  bronchial 
epithelial cells (248), alveolar type II cells (218, 249), and fibroblasts (250).  Like MMP-2, 
MMP-9 has a fibronectin-like repeat allowing for binding to gelatin (251).  MMP-9 can cleave 
gelatins (252), type IV collagen (214), elastin (241), alpha-1-antitrypsin (216), and TGF-β1 
(253), among other substrates.  MMP-9 is upregulated by TGF-β, epidermal growth factor, and 
TNF-α (247).   
Several studies have implicated MMP-2 and MMP-9 in human and experimental 
interstitial lung disease.  The gelatinases’ substrate specificity for type IV collagen indicates a 
role in the degradation of basement membranes (254), and an early event in pulmonary fibrosis is 
the disruption of these basement membranes (255).  Loss of this barrier has been proposed to be 
important for inflammatory cell and fibroblast migration in the lung (256).   
In investigations in humans, levels of MMP-2 and MMP-9 were elevated in lungs and 
BAL fluid of patients with IPF (76, 257).  The upregulation of MMP-2 and -9 may be an 
important discovery since basement membranes are degraded during the course of pulmonary 
fibrosis and since these two MMPs can degrade type IV collagen in basement membranes.  The 
above studies also found an increase in TIMP-2 in IPF (76, 257), which apart from its inhibitory 
capabilities can actually activate MMP-2 through a cell-surface mechanism (258).  These same 
MMPs and TIMPs were also found to be upregulated in myofibroblasts and epithelium of IPF 
patients (75). 
Experimental models of fibrosis have shown similar results.  First, a role for MMPs in 
general in experimental pulmonary fibrosis was definitively shown because the 
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metalloproteinase inhibitor, batimastat, was able to inhibit the development of bleomycin-
induced pulmonary fibrosis (28).  Bleomycin-induced fibrosis in rabbits exhibited an early 
increase in MMP-9 followed by a more chronic expression of MMP-1 and MMP-2 as well as 
TIMP-1 and TIMP-2 (33).  Asbestos exposure to PMNs in vitro caused release of proteases with 
increased “collagenase” activity, but the exact proteases were not identified (259).  The only in 
vivo study examining asbestos and MMPs utilized the less fibrogenic chrysotile fibers and 
revealed increased mRNA for MMP-1 but not MMP-2 or TIMP-1 in response to chrysotile 
alone, and increased mRNA for MMP-2 and TIMP-1 when combined with cigarette smoke 
(260).  MMP-9 and protein levels were not tested.  Experimental lung silicosis also displayed an 
increase in MMP-2 and MMP-9 with reductions in TIMP-1 and TIMP-2 (261).  Another study in 
silica-exposed mice revealed that Clara cell depletion leads to MMP-2 and MMP-9 upregulation, 
suggesting that Clara cells inhibit gelatinase production (262).  Increased gelatinase activity was 
also associated with LPS-induced lung fibrosis (263), paraquat and hyperoxia-induced fibrosis 
(264), and in hyperoxic lung injury (218, 249, 265).  These studies show that the two gelatinases 
may play a role in many lung diseases. 
There is controversy surrounding the data presented above as well as the actual role of 
these MMPs in the lung.  Unlike the other studies, one bleomycin study found increases in 
MMP-2 but not in MMP-9 (266).  Studies in mice null for MMP-9 revealed similar levels of 
pulmonary inflammation after LPS exposure (217, 267).  Furthermore, when these knockout 
mice were instead exposed to bleomycin to induce pulmonary fibrosis, there was no change in 
development of fibrosis at 21 days by histology, collagen content, or elastin content (219).  The 
one phenotype observed was the absence of alveolar bronchiolization in the knockout mice.  
Alveolar bronchiolization describes the migration of bronchial epithelial cells such as Clara and 
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ciliated cells into areas of damaged alveoli, possibly as a repair mechanism.  The loss of this in 
knockout mice indicated that MMP-9 does play a role in bronchial cell migration in the lung, 
irrespective of a negative effect on total fibrosis. 
 
1.6.3. Matrix Metalloproteinase-7 
MMP-7 (matrilysin) has the smallest molecular weight of any of the known MMPs.  It possesses 
only the minimal structure of signal, propeptide, and catalytic domains.  MMP-7 is induced by 
LPS (268), TNF-α, IL-1 (269), and IL-6 (270), while IFN-gamma downregulates it in 
macrophages (271).  MMP-7 can cleave MMP-2 and MMP-9 as well as ADAM28, converting 
them to their active forms (224).  MMP-7 is known to activate the alpha-defensins, an important 
part of the innate immune system (222). 
 MMP-7 was found to have a surprising role in the pathogenesis of pulmonary fibrosis.  
Initial gene microarray analysis performed on lungs from IPF patients and controls revealed that 
the gene most drastically altered was MMP-7, which exhibited increased expression in IPF over 
controls.  When matrilysin knockout mice were given bleomycin, pulmonary fibrosis was 
markedly attenuated compared to wild type mice (244).  It was later discovered that MMP-7 
cleaves syndecans, upon which the mouse KC chemokine is bound.  KC is analogous to the IL-8 
neutrophil chemoattractant in humans.  Without MMP-7, neutrophils could extravasate into the 
lung interstitium from the vasculature, but did not advance into the airspaces.  This attenuation of 
airspace inflammation is thought to explain part of the protection of the MMP-7 knockouts from 
the effects of pulmonary fibrosis (29).   
 In spite of these described roles for MMPs in IPF and bleomycin-induced pulmonary 
fibrosis, the MMPs have not been examined for either their distribution or function in asbestosis.  
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MMPs have also not been evaluated for a role in the regulation of EC-SOD in any disease 
including pulmonary fibrosis.   
 
1.7. CONCLUSIONS 
Idiopathic pulmonary fibrosis and asbestosis are debilitating diseases that currently lack an 
effective treatment or cure.  While many aspects of the development of these diseases are still 
being elucidated, an increasing body of evidence indicates an important role for both 
oxidant/antioxidant and protease/antiprotease imbalances and interactions.  The antioxidant EC-
SOD is expressed at high levels in normal lung but is depleted from lung parenchyma in 
bleomycin-induced pulmonary fibrosis.  This depletion appears to be due to the proteolytic 
cleavage of its heparin-binding domain.  Simultaneous with this depletion is an accumulation of 
EC-SOD in the BAL fluid.  The mechanism underlying this change in EC-SOD is unknown but 
may involve the action of MMPs that are upregulated in pulmonary fibrosis.  In turn, EC-SOD 
may also regulate MMPs through the prevention of oxidative activation of these enzymes.  It is 
therefore hypothesized that depletion of EC-SOD from the lung and interrelated increases 
in MMP enzymes contribute to disease development in pulmonary fibrosis.  To test this 
hypothesis, both EC-SOD and MMPs were examined in a mouse model of asbestosis due to 
amphibole fibers.  Neither EC-SOD nor MMPs have been studied in the context of asbestos-
related fibrotic lung disease.  It is hoped that this research can identify novel mechanisms 
underlying pulmonary fibrosis that can be utilized in future treatments for the disease. 
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2. RATIONALE AND HYPOTHESIS 
Studies in idiopathic pulmonary fibrosis have indicated a role for oxidant/antioxidant imbalance 
in the pathogenesis of the disease.  IPF patients have increased markers of oxidative and 
nitrosative stress (85, 103), and their inflammatory cells are primed to release more ROS than 
normal (115).  Meanwhile, endogenous antioxidant levels are altered in IPF lungs compared to 
normal controls, as glutathione levels are markedly decreased in the lung (118).  Therapy with 
N-acetylcysteine, aimed at restoring this balance by increasing glutathione, has led to improved 
lung function in IPF patients (20).   
 Extracellular superoxide dismutase is an antioxidant enzyme abundant in the lung and 
protective in a variety of experimental lung disease models, including exposure to hyperoxia, 
LPS, and oil fly ash (197, 199, 201).  EC-SOD also protects against the development of 
bleomycin-induced pulmonary fibrosis (202, 204).  Importantly, in the bleomycin model, EC-
SOD is removed from the extracellular matrix of the lung and accumulates in the airspaces (207).  
The mechanism of this depletion is likely the proteolysis of the heparin-binding domain of EC-
SOD, which confers affinity for the matrix.  Loss of this antioxidant from the lung parenchyma 
would increase susceptibility to oxidative stress and possibly enhance progression of the disease.   
 Potential targets of increased oxidative stress in the lung include the matrix 
metalloproteinase family of enzymes.  Members of this family, including MMP-1, MMP-2, 
MMP-7, and MMP-9, have been demonstrated to be upregulated in pulmonary fibrosis (33, 76, 
244).   Possible roles for these MMPs in pulmonary fibrosis include enhancement of cell 
migration through degradation of basement membranes and establishment of chemotactic 
gradients for inflammatory cells (29, 256).  The MMPs are secreted as latent enzymes, requiring 
activation to cleave substrate (128).  Current evidence indicates that ROS can activate these 
MMPs, suggesting a method by which EC-SOD depletion from lung parenchyma could exert 
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pathogenic effects (229).  There is the possibility of positive feedback as well, as MMPs could 
cleave the heparin-binding domain of EC-SOD, leading to further removal from the lung matrix.   
In light of this data, it is hypothesized that depletion of EC-SOD from the lung and 
interrelated increases in MMPs contribute to disease development in pulmonary fibrosis.  To 
study the regulation of EC-SOD and MMPs in this disease, a mouse model of pulmonary fibrosis 
involving the intratracheal instillation of asbestos fibers was utilized.  I also examined the 
potential relationships between EC-SOD and MMPs in an attempt to better understand how 
antioxidants and proteases could contribute through converging pathways to the development of 
pulmonary fibrosis. 
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3. MATERIALS AND METHODS 
 
3.1. ANIMAL MANIPULATIONS 
 
3.1.1. Mice 
8-10 week old C57BL/6 wild type mice were obtained from Taconic (Germantown, NY).  EC-
SOD knockout mice were originally derived by Dr. Stefan Marklund and acquired for breeding 
in our animal facility (196).  These mice were produced on the C57BL/6 background through the 
targeted disruption of the mouse ec-sod gene with a gene encoding neomycin resistance.  EC-
SOD transgenic overexpressing mice were described previously (197).  The entire gene 
encoding human EC-SOD was ligated into a vector containing the surfactant protein C promoter 
which targets expression to type II epithelium and distal bronchial epithelial cells.  Offspring 
resulting from injection of this construct into fertilized eggs were backcrossed into the B6C3 
mouse strain for greater than six generations.  MMP-9 knockout mice and FVB/NJ wild type 
controls were obtained from Jackson Laboratories (Bar Harbor, ME). 
 
3.1.2. Intratracheal instillation of asbestos and bleomycin  
Asbestos and bleomycin animal exposures were reviewed and approved by the University of 
Pittsburgh Institutional Animal Care and Use Committee.  8-10 week old age and sex-matched 
C57BL/6 mice or EC-SOD knockout mice (Taconic, Germantown, NY) were used in 
experiments.  In the case of EC-SOD transgenic overexpressors, nontransgenic littermates were 
utilized as controls.  Males and females did not have significantly different responses in any of 
our experiments.   
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Mice were anesthetized with brief exposure to isoflurane (Abbot Laboratories, Chicago, 
IL) and then intratracheally instilled with 0.1 mg of asbestos, 0.1 mg titanium dioxide (Sigma, St. 
Louis, MO), or 0.9% saline vehicle.  Crocidolite asbestos fibers (>10 µm in length) were used in 
these experiments and were a kind gift of Dr. Andy Ghio at the National Institute of 
Environmental Health Sciences.  In bleomycin experiments, mice were intratracheally instilled 
with 0.06 units of bleomycin sulfate (Bedford Laboratories, Bedford, OH) or saline vehicle.  
Mice were euthanized with an injection of 5 mg pentobarbital (Sigma) at 1, 3, 7, 14, or 28 days, 
as indicated in the results.   
Bronchoalveolar lavage (BAL) fluid was obtained by the intratracheal instillation and 
recovery of 0.8 ml 0.9% saline.  Lungs were removed and flash frozen in liquid nitrogen.  BAL 
and lung samples were stored at -80°C until used for biochemical analyses.  Lungs from some 
mice were inflation fixed with 10% buffered formalin (Fisher Scientific, Pittsburgh, PA) for at 
least 2 hours before overnight incubation in 70% ethanol.  Lungs were paraffin embedded by 
Research Histology Services at the University of Pittsburgh. 
   
3.1.3. MMP inhibition 
In vivo MMP inhibition was performed with the broad spectrum metalloproteinase inhibitor, 
GM6001 (also known as galardin) (EMD Biosciences/Calbiochem, La Jolla, CA).  GM6001 was 
dissolved in dimethyl sulfoxide (Sigma) and aliquots stored at -20°C.  On days of injection, these 
aliquots were thawed and mixed with saline to make a final solution of 1.0 mg/ml in 0.9% saline.  
Mice being treated with GM6001 or vehicle were intraperitoneally injected (0.2 mg per mouse) 
every day for 14 days beginning on day -1.  On day 0, mice were intratracheally instilled with 
0.1 mg asbestos or titanium dioxide.  These mice were euthanized at day 13.   
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 3.1.4. Bacterial Pneumonia studies 
Pneumonia studies were performed in collaboration with Drs. Janet Lee and Thomas Martin at 
the University of Washington.  C57BL/6 breeders were originally obtained from the Jackson 
Laboratory (Bar Harbor, ME) and bred in the vivarium of the VA Puget Sound Health Care 
Systems Research facility.  Age and sex matched animals were used in all experiments.  Animals 
were maintained in specific pathogen free cages.  Bacterial inhalation experiments were 
conducted in accordance with the Institutional Animal Care and Use Committee at the VA Puget 
Sound Health Care Systems and the University of Washington.   
 
3.1.4.1. Bacteria.   
 
E. coli, serotype K-1, was a clinical isolate obtained from the blood of a patient with biliary 
sepsis.  To establish virulence in animals, these bacteria were inoculated into the lungs of a 
specific pathogen free New Zealand White rabbit.  After 24 hours, the blood and spleen 
homogenates were diluted and added to LB agar using the pour plate method and colonies 
allowed to form.  These bacteria were frozen at -70°C.  Before an experiment an aliquot of 
frozen bacteria was thawed and inoculated into 50 mL of Luria broth (Gibco-BRL Laboratories, 
Gaithersburg, MD) which was incubated for 6 h at 37°C shaking at 225 rpm.  For the aerosol 
experiments, this culture was inoculated into 1 L of Luria broth and incubated for another 14 h 
under the same conditions.  The broth was centrifuged at 9,000 rpm, and the bacterial pellet was 
washed twice with sterile 0.9% NaCl.  The washed bacterial pellet was resuspended in 22 mL 
0.9% NaCl, and divided equally into two nebulizers.  Quantitative cultures were performed on 
the bacterial slurry.  
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3.1.4.2. Bacterial inhalation exposures.   
 
Mice were placed in wire-mesh cages placed inside a closed aerosolization chamber.  The 
bacterial suspension was placed in twin 10-mL nebulizers and applied as an aerosol at 15 lb/in2 
for 30 minutes.  Following bacterial delivery, the mice were either euthanatized immediately in 
order to establish the initial bacterial inoculum, or euthanized at 24 h for measurements of 
bacterial burden.  Mice were euthanatized with 120 mg/kg pentobarbital and exsanguinated by 
direct cardiac puncture.  The thoracic cavity was opened by midline incision.  The trachea was 
exposed and cannulated with a 20 gauge catheter, which was secured with a 2-0 silk suture.  The 
left mainstem bronchus was identified, divided at the hilum, and the entire left lung was placed 
in 1 mL sterile H2O for subsequent homogenization.  Bronchoalveolar lavage (BAL) was 
performed on the right lung using 0.9% NaCl containing 0.6 mM EDTA instilled in one aliquot 
of 0.6 ml, followed by 3 aliquots of 0.5 ml.  The right lung was subsequently fixed with 4% 
paraformaldehyde at an inflation pressure of 15 cm H20.  Quantitative cultures of bacterial 
burden were performed on the lung homogenates obtained from each animal at 0, 6, and 24 hours 
by spreading serial 10-fold dilutions of the lung homogenates in warm LB agar using the pour 
plate method.   
 
3.2. HUMAN IPF STUDIES 
Frozen unfixed lung samples were provided by the University of Pittsburgh Tissue Bank.  Four 
pulmonary fibrosis lung samples were obtained from patients with pathologically-identified 
Usual Interstitial Pneumonia.  Lung samples were embedded in OCT medium and 5 µm sections 
cut from the blocks using a cryostat.  These slides were stained with hematoxylin and eosin as 
described above.  Regions of histologically normal alveolar parenchyma and areas of fibrotic 
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lung were identified histologically and used to guide the excision of these regions of tissue from 
the frozen blocks.  Care was taken to avoid bronchi and bronchioles as well as large blood 
vessels since these structures contain large amounts of EC-SOD.  The tissue was homogenized 
and sonicated in 10 volumes buffer as described in 3.3.2. After centrifugation, the supernatant 
was isolated and protein concentrations measured with the Coomassie Plus Protein Assay 
Reagent (Pierce).  Samples were subjected to reducing SDS-PAGE as described in Chapter 3.3.4. 
 
3.3. BIOCHEMICAL AND CELLULAR ANALYSES 
 
3.3.1. Bronchoalveolar lavage fluid analysis.   
For the asbestos and bleomycin experiments, total protein was determined using the Coomassie 
Plus Protein Assay Reagent (Pierce, Rockford, IL).  Total white blood cell counts were obtained 
using a Beckman Z1 Coulter Particle Counter (Beckman Coulter, Fullerton, CA) set to count 
particles greater than 6 µm in diameter.  The cell concentrations obtained were multiplied by the 
total BAL volume recovered from the mouse to determine total (absolute) cell counts.  To obtain 
a differential count, 100 µL of BAL fluid (diluted 1:2 for asbestos samples) were adhered to 
glass slides with a cytospin and stained with Diff Quik reagents (Dade Behring Inc., Newark 
DE).  Numbers of macrophages, neutrophils, lymphocytes, and eosinophils were counted under a 
microscope until a total of 400 cells were counted for each mouse.  The percentages derived 
from this count were multiplied by the total cell count obtained on the Coulter counter to obtain 
total numbers of each type of leukocyte. 
 For the pneumonia experiments, total cell counts in the BAL fluid were performed using 
a Neubauer chamber.  Cell differentials were performed by counting 200 consecutive cells from 
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cytospin preparations stained with Diff Quik.  The remainder of the BAL fluid was spun at 200 x 
g, and supernatants were stored at –70oC.   
 
3.3.2. Lung homogenization. 
Lungs from asbestos and bleomycin studies were homogenized and sonicated in 50 mM 
potassium phosphate (pH 7.4) with 0.3 M potassium bromide and containing 3 mM 
diethylenetriaminepentacetic acid and 0.5 mM phenylmethylsulfonylfluoride.  Homogenates 
were centrifuged at 20,000 x g for 20 minutes.  The supernatant was recovered and the insoluble 
pellet subjected to detergent re-extraction using a 50mM Tris-HCl, 150mM NaCl, 10mM 
CHAPS detergent buffer, pH 7.4, containing 100 µM dichloroisocoumarin (serine protease 
inhibitor) and 10 µM E-64 (cysteine protease inhibitor).  CHAPS detergent aids in the extraction 
of MMPs (272).  Total protein concentration determinations were made using the Coomassie 
Plus Protein Assay reagent (Pierce).  All homogenates were stored at –70oC.   
 For the pneumonia experiments, the left lung homogenates were separated into aliquots 
for quantitative cultures, western blot analysis, and myeloperoxidase determinations.  For the 
western blots, the lung homogenate was added to a buffer containing 0.5% Triton-X-100, 150 
mM NaCl, 15 mM Tris, 1 mM CaCl2 and 1 mM MgCl2 (pH 7.4), incubated on ice for 30 
minutes, and spun at 10,000 x g for 20 minutes.  The supernatants were stored at –70oC.  For the 
MPO measurements, the lung homogenate was added to a buffer containing 50 mM potassium 
phosphate (pH 6.0), 5 mM EDTA, and 5% w/v hexadecyltrimethyl ammonium bromide.  The 
mixture was sonicated, spun at 12,000 x g for 30 minutes, and the supernatants were stored at –
70oC. 
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3.3.3. EC-SOD Activity Assay   
After an aliquot was removed from lung homogenate supernatants (obtained before CHAPS 
detergent extraction) for western blotting, the remaining homogenate was passed over a 
concanavalin A Sepharose (Sigma) in a polystyrene mini-column (Pierce) equilibrated with 50 
mM HEPES (pH 7.0), 0.25 M NaCl.  This column binds EC-SOD but not other SODs (207).  
After elution from the column with 0.5 M α-methylmannoside, the separated EC-SOD was 
concentrated with Centriprep-30 concentrators (Millipore, Bedford, MA).     
EC-SOD activity was measured by inhibition of the reduction of partially acetylated 
cytochrome c (Sigma) by superoxide at pH 10.  Xanthine (50 mM) (Sigma) and xanthine oxidase 
(Boehringer Mannheim, Germany) were utilized to generate superoxide.  The xanthine oxidase 
was titrated until change in absorbance per minute of cytochrome c equaled 0.025.  Samples 
(lung homogenates or BAL fluid) were added to the cytochrome c/xanthine/xanthine oxidase and 
titrated until 1 SOD unit was achieved and then measurements repeated 3 times.  SOD units were 
calculated as: [ (rate without sample / rate with sample) – 1 ].  The average was divided by the 
sample volume required to achieve the SOD unit to express as SOD units per mL.  These values 
were normalized to gram weight of lung for lung homogenate samples.  In the case of BAL fluid, 
measurements were normalized to BAL volume. 
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3.3.4. Western blot analysis.   
BAL fluid or lung homogenates samples were boiled for 10 minutes in the presence of 50 mM 
DTT and 1% SDS and subjected to SDS-PAGE using a Mini-slab gel system (Idea Scientific, 
Minneapolis, MN) and blotted onto PVDF membranes (Millipore, Bedford, MA) at 500 mA 
using a Hoefer TE series transfer unit (Hoefer, San Francisco, CA).  Equal protein loading was 
used for all western blots.  Typically, 5 to 10 µg of protein were loaded onto a gel.  Blots were 
blocked overnight in 5% milk in phosphate buffered saline with 0.3% Tween-20 (PBST) before 
application of primary antibodies.   
Antibodies were all diluted in PBST.  Antibody to detect mouse EC-SOD on blots 
(1:10,000 dilution) was generated against the whole protein and was previously described (207).  
The same antibody detects human EC-SOD in SPC EC-SOD transgenic mice at the same 
dilution. In human UIP studies, EC-SOD was detected with an antibody specifically directed 
against human EC-SOD (1:5,000 dilution).  TIMP-1 was detected with antibody at a 1:1,000 
dilution (Triple Point Biologics, Forest Grove, OR).  TIMP-2 was detected with antibody at 
1:200 dilution (Chemicon, Temecula, CA).  Secondary antibodies conjugated to horseradish 
peroxidase were added to blots for detection.  Donkey anti-rabbit IgG antibodies (Amerhsam 
Biosciences/GE Healthcare Piscataway, NJ) were used at a 1:5,000 dilution while sheep anti-
mouse IgG antibodies (Amersham/GE) were used at a 1:10,000 dilution.  All of the primary 
antibodies were made in rabbits except the TIMP-2 antibody, which was made in mouse.  ECL 
detection reagents (Amersham/GE) were utilized to visualize bands.  Blots were stripped and 
reprobed with antibody against β-actin at a 1:5,000 dilution (Sigma) as a loading control.  
Densitometry was performed to quantify band intensity and standardized to β-actin using Kodak 
1D software (Rochester, NY).   
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3.3.5. Gelatin Zymography.   
To quantify protein levels of MMP-2 and MMP-9, BAL fluid or lung homogenates were 
subjected to gelatin zymography.  Equal protein samples of BAL fluid (5 µg) or the CHAPS 
detergent extractions (15 µg) of lung homogenates were applied to 10% SDS/PAGE gels 
containing gelatin (Invitrogen, Carlsbad, CA).  After completion of electrophoresis, the gel was 
washed in Triton X-100 (Fisher, Pittsburgh, PA) and incubated for 22-24 hours at 37°C in pH 7.4 
buffer containing 5 mM calcium and 1 µM zinc.  After staining of the gel with Coomassie 
Staining Solution (40% methanol, 13.3% glacial acetic acid, 0.1% Coomassie Brilliant Blue 
(Fisher)), areas of MMP activity appeared as clear bands.  Purified mouse MMP-2 (Calbiochem, 
Temecula, CA) and MMP-9 (EMD Biosciences, San Diego, CA) and MMP-2 and MMP-9 
samples purified from liver homogenates using gelatin-sepharose (Amersham/GE) were used to 
identify the bands as MMP-2 and MMP-9.  Densitometry was performed with Kodak 1D 
software as described in the western blotting methods above.   
 
3.3.6. Hydroxyproline Assay. 
Whole lungs were dried and acid hydrolyzed in sealed, oxygen-purged glass ampoules 
containing 2 ml of 6 N HCl for 24 hours at 110ºC.  Samples were again dried and then 
resuspended in 1.5 ml phosphate buffered saline followed by incubation at 60ºC for 1 hour.  
Samples were centrifuged at 13,000 rpm for 10 minutes and the supernatant taken for 
hydroxyproline analysis.   
 Hydroxyproline was measured by the addition of 2 mL of diluted sample (typically 1:40) 
to a 1 mL solution of 50 mM chloramine T (Sigma), 30% methyl cellusolve (ethylene glycol 
monomethyl ether) (Sigma), and buffer (0.12 M citric acid, 0.45 M sodium acetate, 0.425 M 
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sodium hydroxide, 0.6% glacial acetic acid, pH 6).   After a 20 minute incubation at room 
temperature, 1 mL of 3.15 M perchloric acid was added and incubated for 5 minutes.  1 mL of 
1.34 M p-dimethylaminobenzaldehyde was added and incubated at 60ºC for 20 minutes.  
Samples were read in 96 well plates in triplicate at 557 nm.  Concentration values were 
multiplied by dilution factor and divided by two to achieve µg/lung units. 
 
3.3.7. MPO activity assay.   
The Amplex Red peroxidase assay kit (Molecular Probes, Eugene, OR, USA) was used to 
determine MPO activity in the lung homogenates.  Lung tissue homogenates were prepared as 
above, and then mixed with reaction buffer, H2O2, and Amplex Red reagent according to the 
manufacturer’s instructions.  The Amplex Red reagent reacts with H2O2 in the presence of 
peroxidase to produce the fluorescent molecule resorufin.  The fluorescence of each sample was 
measured using a cytofluorometer set at excitation wavelength 530 nm and emission wavelength 
590 nm (CytoFluor II, PerSeptive Biosystems, Foster City, CA, USA).  The MPO activity was 
obtained by calculating resorufin units for each unknown lung homogenate sample using a 
resorufin standard curve.   
 
3.3.8. RNA isolation. 
Lungs to be used for RNA isolation were recovered from mice and immediately flash frozen 
with liquid nitrogen.  RNA was isolated using the RNeasy Maxi Kit (Qiagen, Valencia, CA) as 
per the manufacturer’s instructions.  Whole frozen lungs were homogenized in buffer RLT 
containing 0.143 M beta-mercaptoethanol.  After centrifugation (3000 g x 5 minutes), 
supernatant was recovered and mixed with 70% ethanol.  This mixture was added to an RNeasy 
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Maxi column and centrifuged again.  After several washes of the column, RNase free DNase 
(Qiagen) was added to the filter membrane for 15 minutes to remove contaminating DNA.  
Additional washes were followed by recovery of RNA from the filter with two elutions using 0.8 
mL water each time.     
 
3.3.9. Quantitative reverse transcriptase polymerase chain reaction. 
Isolated RNA was examined for EC-SOD mRNA message using Taqman Gene Expression 
Assays (Applied Biosystems, Foster City, CA).  RNA (1 µg) was first subjected to a reverse 
transcriptase reaction using 2 µL 10X PCR buffer II, 4 µL 25mM MgCl2, 2 µL dNTP mix 
(10mM stock of each nucleotide), 1 µL random hexamer primers (3 µg), 1 µL RNasin (1 U) and 
1 µL MuLV reverse transcriptase (2.5 U)(all from Applied Biosystems) per 20 µL reaction to 
create cDNA.  The following program was used on a thermocycler for reverse transcription: 40 
min at 42°C, 5 min at 99°, 5 min at 5°.  After the run, water was added to bring the final volume 
of each sample to 50 µL.  Each 50 µL reaction received 9 µL of the cDNA, 25 µL 2X Universal 
PCR buffer, and 2.5 µL 20X expression assay buffer (Applied Biosystems) for either mouse EC-
SOD as the target or mouse GAPDH as endogenous control.  Reactions were done in triplicate 
wells of a 96-well PCR plate (USA Scientific, Ocala, FL) with GAPDH as an endogenous 
control used in duplicate.  Quantitative analysis was then performed on an ABI SDS7000 
(Applied Biosystems).  Crossing thresholds for EC-SOD were obtained and divided by the 
crossing threshold for GAPDH.  The results were averaged for each group.  
 
50 
3.4. HISTOLOGICAL ANALYSES 
 
3.4.1. Hematoxylin and eosin histology staining. 
5 µm sections were cut from paraffin embedded blocks using a microtome and floated in a 37ºC 
water bath before adherence to positively charged glass slides (Fisher).  Slides were baked at 
60ºC overnight before staining procedures were performed.  Slides were deparaffinized by dips 
in xylene, followed by graded swishes in ethanol (100% to 95% to 70%) and water before 1 
minute incubation in Gill’s hematoxylin (Vector Laboratories, Burlingame, CA) and 5 seconds in 
0.1% eosin Y, 0.01% phloxine B, 85% EtOH, 5% glacial acetic acid solution.  Slides were then 
dipped in graded ethanol (70% to 95% to 100%) and xylene and coverslipped.   
 
3.4.2. Histological Scoring.   
Hematoxylin and eosin stained slides were scored by a pathologist (Tim Oury) blinded to sample 
groups.  Individual fields were examined with a light microscope at high power (400X) 
magnification.  Every other field was scored in a spiraling pattern beginning peripherally in the 
lung and ending more centrally until twenty fields were counted for each slide.  In order to be 
counted, each field had to contain alveolar tissue in greater than 50% of the field.  Scoring in 
each field was based on the percentage of alveolar tissue with interstitial fibrosis according to the 
following  scale:  0 = no fibrosis, 1 = up to 25%, 2 = 25-50%, 3 = 50-75%, 4 = 75-100%.   
 
3.4.3. Immunohistochemistry. 
Immunohistochemistry for EC-SOD was performed on 5 µm sections from paraffin-embedded 
mouse lungs using an automated slide staining system (Dako, Carpinteria, CA).  Slides were 
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deparaffinized by overnight baking at 60ºC and by three 20 minute incubations in Clear Rite 
(Richard Allen Scientific, Kalamazoo, MI).  Slides were then dipped in 100% ethanol followed 
by 95% ethanol and incubated in 6% hydrogen peroxide in methanol (30 minutes) to inactivate 
endogenous peroxidases.  This was followed by a incubation in 0.1% pepsin in 0.01 N HCl (10 
minutes) for antigen retrieval.  After blocking with Maxitags Protein Blocking Agent (Thermo 
Electron, Pittsburgh, PA) (30 minutes), slides were incubated with the same antibody against 
mouse EC-SOD (1:500) used in western blotting or with normal rabbit sera as a control for 60 
min.  A 30 min incubation in biotinylated secondary antibody (1:1000) was followed by 
incubation in ABC reagent (Vector Laboratories) for 30 min.  Slides were developed with the 
Nova Red staining kit (Vector).  All slides were stained on the same day and developed for the 
same amount of time.  Slides were not counterstained.  Photos of ten random fields from each 
slide taken at 400X magnification were analyzed for EC-SOD staining intensity using 
Metamorph software (Molecular Devices, Sunnyvale, CA).  We have previously shown that 
quantification of EC-SOD staining in immunoperoxidase-stained slides using this method 
produces similar results compared with immunofluorescence staining (208). 
To examine MMP-2 levels, goat antibody directed against this MMP (R&D Systems, 
Minneapolis, MN) was utilized in the same protocol listed above for EC-SOD except that slides 
were counterstained in Gill’s Hematoxylin (Vector Laboratories) for 1 minute following Nova 
Red staining.  Anti-MMP-2 antibody was used at a 1:25 concentration and secondary 
biotinylated anti-goat antibody (ICN, Costa Mesa, CA) was utilized at a 1:500 dilution.  
Similarly goat anti-MMP-9 antibody (R&D Systems) was used at a 1:50 concentration with 
secondary biotinylated anti-goat at 1:500 dilution (ICN).  As a negative control, normal goat IgG 
(R&D Systems) was utilized at the same concentration as the primary antibody.  
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3.5. STATISTICAL ANALYSES 
Data are provided as means +/- standard error of measurement (SEM).  All comparisons between 
two groups were made using a Student’s t test.  All comparisons between more than two groups 
were made by one way ANOVA with Tukey’s post test.  The Graphpad Prism 4 statistical 
software package (Graphpad, San Diego, CA) was used for all statistical testing.  A P value of 
less than or equal to 0.05 was considered statistically significant. 
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4. ASBESTOS INDUCES PULMONARY INFLAMMATION AND FIBROSIS 
In order to examine the role of EC-SOD and MMPs in pulmonary fibrosis, we first designed and 
characterized a model of pulmonary fibrosis after intratracheal instillation of asbestos fibers.  
Although bleomycin is still the most commonly used agent to experimentally induce fibrosis in 
the lung, bleomycin does not recapitulate many of the findings of human IPF, including the 
development of fibroblastic foci (3).  Also, in the mouse, bleomycin fibrotic lesions are self-
limiting and mice will not progress to respiratory failure (273).  Bleomycin is also metabolized 
within 24 hours of exposure (273).  Asbestos, on the other hand, would not be metabolized, and 
pathogenesis may be more indicative of the human disease.  Furthermore, asbestos is clearly a 
better model to study asbestosis. 
 
4.1. ASBESTOS EXPOSURE CAUSES NEUTROPHILIC INFLAMMATION AND 
EPITHELIAL/ENDOTHELIAL BARRIER BREAKDOWN 
C57BL/6 wild type mice were intratracheally instilled with 0.1 mg of crocidolite asbestos to 
determine their effects on the lung.  Control mice were instead treated with vehicle (0.9% sterile 
saline) or with an inert particulate control, titanium dioxide (TiO2).  To assess the acute effects 
of asbestos exposure, mice were euthanized at 24 hours and bronchoalveolar lavage (BAL) fluid 
was collected.  Lungs were recovered for either histology or homogenization.   
 In Figure 3, histology of asbestos-exposed lungs shows a dramatic change compared to 
control lungs.  Asbestos fibers can be found in bronchioles and alveolar regions, and are usually 
accompanied by inflammatory aggregates and interstitial thickening and edema.  The majority of 
the inflammatory cells possessed segmented nuclei typical of polymorphonuclear neutrophils 
(PMNs).  As expected, there were no signs of fibrosis at this early timepoint. 
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 Figure 3.  Asbestos induces pulmonary inflammation and edema 24 hours after exposure. 
C57BL/6 mice were intratrachaelly instilled with saline or 0.1 mg crocidolite asbestos.  Mice were euthanized 
at 24 hours and the lungs inflation-fixed in formalin.  Hematoxylin and eosin staining was performed on lung 
sections from mice exposed to saline (A) or asbestos (B, C).   Mice exposed to titanium dioxide (not shown) 
looked identical to saline-treated mice in panel A.  Asbestos fibers are shown with an arrow. Boxed area (in 
C) is shown at greater magnification (in D) to show fibers in detail.  Bar equals 25 µm.  
 
 
BAL fluid analyses, as a sampling of airspace protein and cell content, also indicated 
significant inflammation and damage.  BAL fluid protein was markedly elevated in the asbestos 
mice when compared to either saline or TiO2 controls (Figure 4).  This protein accumulation 
indicates increased permeability between the vascular and alveolar airspaces.  The total number 
of white blood cells were also counted and revealed intense inflammation in the lung (Figure 5).  
When BAL fluid differentials were counted, the majority of these cells were determined to be 
neutrophils (Figure 6 and Figure 7).  Macrophages could also be found and in some cases were 
observed unsuccessfully phagocytosing asbestos fibers.  This represents “frustrated” 
phagocytosis, which is discussed in the introduction (see Chapter 1.4.6).   
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Figure 4.  Asbestos increases total protein in the bronchoalveolar lavage (BAL) fluid. 
BAL fluid was recovered by instillation and recovery of 0.8 mL saline at the indicated timepoints after 
instillation of titanium dioxide (TiO2) or asbestos.  Total protein was determined using the Coomassie Plus 
protein reagent assay.  Higher protein levels indicate endothelial-epithelial layer permeability, an indicator of 
lung damage.  *p < 0.05, Student’s t test.    
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Figure 5.  Asbestos exposure causes airspace inflammation. 
White blood cell concentrations (cells/ml) in BAL fluid were counted on a Coulter particle counter at the 
indicated timepoints post-asbestos or titanium dioxide (TiO2) exposure.  Total BAL fluid cells were 
calculated as concentrations times total volume of BAL fluid recovered.  *p < 0.05, Student’s t test.   
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Mice were also euthanized at longer timepoints post-asbestos instillation in order to 
determine whether fibrosis developed in response to asbestos.  The BAL fluid parameters 
showed some attenuation at the later timepoints.  The BAL fluid protein levels remained 
significantly elevated (Figure 4), while total inflammation subsided by 14 days (Figure 5).  
However, there was still a significant increase in neutrophils in the BAL fluid at 7, 14, and 28 
days (Figure 7). 
 
A) Saline B) TiO2
C) Asbestos D) Asbestos
 
Figure 6.  Asbestos expsoure increases airspace PMN at 24 hours post-instillation. 
24 hours after intratracheal instillation with saline, TiO2, or asbestos, BAL fluid was recovered and spun 
onto slides and subjected to Diff Quik staining for leukocytes.  A) BAL cells from saline-treated mice are 
shown as a reference and contain normal alveolar macrophages.  B)  TiO2-treated mice show macrophages 
engulfing black titanium particles and a few scattered PMN.  C)  Asbestos-exposed mice have a large increase 
in PMN content.  D)  A macrophage attempting (frustrated) phagocytosis of an asbestos fiber.  The relative 
quantities of cells on each slide carries no significance as the BAL fluid was diluted to different amounts in 
each slide.  Bar equals 50 µm. 
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Figure 7.  PMN are increased after asbestos exposure. 
Wild type mice were intratracheally instilled with saline, titanium dioxide (TiO2), or asbestos. BAL fluid was 
recovered at 1, 7, 14, and 28 days.  Differential counts were performed on cytospins.  Asbestos-exposed mice 
had fewer macrophages at 24 hours (A).  These mice also had greater amounts of neutrophils at all timepoints 
(B).  Saline and TiO2 controls were not significantly different from each other at 24 hours.  
* p < 0.05, one way ANOVA and Tukey’s post test in top figure, or Student’s t test in bottom figure, 
comparing control(s) and asbestos at each timepoint. 
 
4.2. ASBESTOS EXPOSURE CAUSES PULMONARY FIBROSIS 
 The major change observed at later timepoints was the development of fibrosis.  At 7 
days in asbestos-exposed mice, inflammation and a small amount of fibrosis was observed by 
histology (Figure 8).  Fibrosis surrounded the bronchioles, in agreement with what is found early 
in human asbestosis (21).  Lungs from mice sacrificed 14 and 28 days after asbestos revealed 
progressively more fibrosis and a greater involvement of alveolar septa.  Some evidence was also 
found for the development of fibroblastic foci, described as loose fibrosis populated by 
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myofibroblasts scattered at the edges of this fibrosis (14).  This is evidence that our asbestos 
model is more akin, at least histopathologically, to IPF than the bleomycin model. 
 
A)
C)
B)
D)
 
Figure 8.  Fibrosis in mouse lungs 7-28 days after asbestos exposure. 
Mice were sacrificed at 7, 14, and 28 days post asbestos exposure.  Standard hematoxylin and eosin staining 
was performed on 5 µm lung sections.  A) 7 day lungs possessed inflammation and minimal fibrosis, localizing 
to the areas around the bronchioles.  Compare with normal lung section in Figure 3A.  B) 14 day lungs 
possess increased fibrosis, extending into alveolar walls.  C)  28 day lung with extensive fibrosis in one lobe 
next to a normal lobe.  D)  28 day lung displaying a structure resembling a fibroblastic focus (arrow) with 
myofibroblasts in loose connective tissue).  Bar equals 50 µm.  
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Figure 9.  Fibrosis is increased 14 days after asbetos exposure. 
Fibrosis was measured in wild type C57BL/6 mice 14 days after exposure to asbestos.  A) Average histology 
score was determined by a blinded pathologist (T.D.O.) for TiO2- and asbestos-treated mice.  Scoring system 
was as follows: 0=no fibrosis, 1=0-25% fibrosis, 2=25-50%, 3=50-75%, 4=75-100%.  B) Hydroxyproline levels 
were determined as an indicator of fibrosis.  * p < 0.05, Student’s t test. 
 
4.3. CONCLUSIONS 
Intratracheal instillation of asbestos in mice is associated with a significant inflammatory 
response at 24 hours predominated by PMNs.  PMNs remain elevated until at least 28 days post-
exposure.  The lungs enter a fibrotic phase of excess collagen deposition affecting bronciholes as 
early as day 7 and progressing into alveolar regions at 14 and 28 days.  These results indicate 
that our asbestos model closely approximates the changes observed in human asbestosis.  The 
rapid progression of pathologic lesions, leading to significant levels of fibrosis at 14 days (Figure 
9), facilitates study of the molecular mechanisms of this disease throughout its development.  
Importantly, neither EC-SOD nor MMPs have been examined in the current literature of 
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asbestosis.  Furthermore, because of the presence of fibroblastic foci, our model may more 
closely approximate human IPF than the bleomycin model (which lacks these lesions) since 
these foci are hallmarks of IPF.   
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5. ASBESTOS EXPOSURE ALTERS EC-SOD LOCALIZATION IN THE LUNG 
Because of previous studies describing a redistribution of EC-SOD in pulmonary disease (207, 
208), it was hypothesized that our asbestos model would also reveal changes in EC-SOD 
localization.  To test this hypothesis, I examined BAL fluid and lung homogenates from mice 
treated with asbestos.  A change in antioxidant status in the lung could play a role in the 
pathogenesis of disease, particularly in light of the oxidative stress attributed to asbestos fibers 
(158).  
 
5.1. ACUTE ASBESTOS EXPOSURE DEPLETES EC-SOD FROM LUNG 
PARENCHYMA 
Wild type mice were intratracheally instilled with asbestos and euthanized at 24 hours.  Lungs 
were homogenized, and EC-SOD was isolated from the other SOD enzymes using a 
concanavalin A column.  Using a well-established method to measure SOD activity using 
cytochrome c (207, 208), the amount of EC-SOD activity in the lung was determined.  As shown 
in Figure 10, total lung EC-SOD activity was decreased in asbestos-treated mice compared to 
controls. 
Western blots were performed to verify our activity assay, and to determine whether loss 
in activity is due to loss of protein or to protein inactivation.  Lung homogenates from mice were 
subjected to reducing SDS-PAGE to dissociate EC-SOD into its component monomers.  EC-
SOD monomers migrate as doublets on electrophoresis because of the presence or absence of the 
heparin binding domain, leading to two different molecular weights.  Western blots revealed a 
decrease in EC-SOD in the lung at 24 hours (Figure 11).  
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Figure 10.  EC-SOD activity decreases after exposure to asbestos. 
EC-SOD was isolated and concentrated from lung homogenates of mice treated 24 hours previously with 
saline or asbestos (N=9).  Activity was assessed via the inhibition of cytochrome c at pH 10.  * p < 0.05, 
Student’s t test. 
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Figure 11.  EC-SOD protein is depleted from the lung 24 hours after asbestos. 
Lung homogenates (10 µg) from mice treated with saline, TiO2, and asbestos (0.1 mg) were subjected to 
reducing SDS-PAGE.  Western blotting was performed and blots probed with antibody against mouse EC-
SOD (1:10,000 dilution).  Blots were stripped and reprobed with antibody against beta-actin (1:5,000) as a 
loading control.  * p < 0.05 one way ANOVA and Tukey’s post test. 
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 To determine whether EC-SOD depletion is due to a loss from the lung parenchyma, 
quantitative immunohistochemistry was performed.  Five micron, paraffin-embedded sections 
were stained with antibody directed against mouse EC-SOD.  After staining with a chromogenic 
substrate, slides were subjected to morphometric analysis for staining intensity using Metamorph 
software.  In normal lungs from mice that did not receive asbestos, EC-SOD was found lining the 
alveolar septa with intense staining (Figure 12).  EC-SOD was also localized to pulmonary 
vasculature and bronchiolar epithelium.  In asbestos-treated mice sacrificed at 24 hours, EC-SOD 
staining in alveolar septa was dramatically reduced.  This indicated that the observed depletion 
of EC-SOD was due to loss from the parenchyma.  This depletion from the lung is significant, as 
this could lead to greater oxidative stress in this area of the lung and progression of the disease.  
While the depletion of EC-SOD from lung parenchyma is more dramatic on 
immunohistochemistry than on western blots, it must be noted that western blots are performed 
on total lung homogenates.  As intratracheal instillation of asbestos leads to heterogeneous injury 
throughout the lung, the normal areas of lung still have normal levels of EC-SOD.  This would 
dilute the effect in total lung homogenates followed by western blotting. 
 EC-SOD expression at the mRNA level was determined through the use of quantitative 
reverse transcriptase polymerase chain reaction (Figure 13).  Using this technique, we found that 
expression of EC-SOD in total lung RNA isolates was markedly decreased after asbestos 
treatment.  This may in part explain the decrease in EC-SOD in the lung.   
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Figure 12.  Asbestos leads to depletion of EC-SOD from lung parenchyma 24 hours post-instillation. 
Immunohistochemistry was performed on paraffin embedded slides from saline-treated (A) and asbestos-
treated (B) mice 24 hours after asbestos exposure.  The same EC-SOD antibody used in western blotting 
(1:500 dilution) was used for slide staining.  All slides were developed on the same day for the same amount of 
time.  Ten random fields from each slide (N=4-5 for each group) were photographed and subjected to 
Metamorph software analysis to quantify staining intensity.   * p < 0.05, Student’s t test 
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Figure 13.  Lung EC-SOD expression decreases after asbestos exposure. 
Quantitative reverse transcriptase polymerase chain reaction was performed on 1 µg total RNA extracted 
from the lungs of mice treated with 0.1 mg crocidolite asbestos.  N=3 for each timepoint.  Crossing thresholds 
were determined and averaged for each group.  Higher thresholds denote less EC-SOD expression.  * p < 0.05 
compared to TiO2, one way ANOVA and Tukey’s post test. 
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5.2. EC-SOD ACCUMULATES IN AIRSPACES AFTER ACUTE ASBESTOS  
Although we demonstrated the depletion of EC-SOD from lungs due to the inhalation of 
asbestos, the fate of the parenchymal EC-SOD was unknown.  Based on the presence of the 
heparin-binding domain of EC-SOD, and the propensity for this binding domain to be 
proteolytically cleaved from the enzyme (176), we hypothesized that EC-SOD was being cleared 
from lung parenchyma due to the action of proteases.  Cleaved EC-SOD would have reduced 
affinity for extracellular matrices.  In theory, this cleaved EC-SOD could diffuse into the 
airspaces of the lung or the plasma.  The breakdown of endothelial and epithelial barriers, as 
indicated by the presence of protein and inflammation in the bronchoalveolar lavage (BAL) 
fluid, would facilitate this diffusion.  We therefore examined BAL fluid for the presence of EC-
SOD by western blotting.   
 Figure 14 shows the western blot for BAL fluid recovered from mice euthanized 24 hours 
post-asbestos treatment.  Compared to control mice, asbestos-exposed mice had significantly 
greater accumulation of EC-SOD in the BAL fluid.  This accumulation is unlikely to originate 
from plasma leakage into the lung since EC-SOD levels in the plasma are normally undetectable.  
Plasma leakage due to endothelial/epithelial breakdown is therefore more likely to dilute lung 
EC-SOD than contribute to its levels, causing underestimation of the BAL fluid EC-SOD.   
Furthermore, the majority of this EC-SOD was the proteolyzed form lacking the heparin-
binding domain.  This indicated that the airspace EC-SOD could arise from full length EC-SOD 
in the lung parenchyma that was proteolyzed and released from the matrix.  This truncated EC-
SOD would then diffuse in the airspace, where it accumulates.  However, inflammatory cells 
such as neutrophils and macrophages produce EC-SOD (184, 207).  Thus, the intense 
inflammation seen in asbestos-mediated lung disease could also be a source of airspace EC-SOD.    
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Figure 14.  Acute asbestos exposure leads to accumulation of proteolyzed EC-SOD in the airspace. 
Western blotting was performed on BAL fluid (equal protein loaded, 10 µg) from mice sacrificed 24 hours 
after intratracheal administration of 0.1 mg crocidolite asbestos.  Densitometry was performed and total EC-
SOD and cut/uncut ratio (i.e. proteolyzed/full length) EC-SOD was determined.  * p<0.05 Student’s t test.  
 
5.3. EC-SOD CHANGES PERSIST AT LATER TIMEPOINTS 
To examine whether the localization changes in EC-SOD are a result of processes occurring only 
early after asbestos damage or whether the change is more permanent, we determined EC-SOD 
levels in the BAL fluid and lung at 7, 14, and 28 days.  As shown in Figure 15, depletion of EC-
SOD from lung homogenates persists at later timepoints.  Similarly, the BAL fluid reveals that 
airspace levels of EC-SOD are increased after asbestos treatment, even at 7, 14, and 28 days 
(Figure 16).  EC-SOD expression is also decreased at 7 days but appears to recover by 14 days 
(Figure 13).  This data shows that the localization changes in EC-SOD are long lived and that the 
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loss of EC-SOD from lung parenchyma is chronic.  This suggests that the lungs possess less 
antioxidant protection at all timepoints during the course of asbestos-mediated lung disease.  
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Figure 15.  EC-SOD is depleted from lung 7, 14, and 28 days after asbestos exposure. 
Western blotting was performed on equal protein amounts of lung homogenates (10 µg) from mice treated 
with asbestos and sacrificed at the times indicated.  Densitometry was performed and normalized to β-actin 
as a loading control.  Densitometry values were expressed as percent of control at that timepoint.  Results 
indicated a loss of EC-SOD in lung homogenates of asbestos mice at all timepoints.   
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5.4. CONCLUSIONS 
An oxidant/antioxidant imbalance is theorized to underlie the pathogenesis of asbestos-mediated 
lung disease.  Asbestos exposure in vitro and in vivo leads to ROS formation detectable through 
markers of oxidative stress (156, 158).  Asbestos also upregulates antioxidants such as 
manganese superoxide dismutase and glutathione peroxidase, signifying a compensatory 
response to oxidative stress (161).    
EC-SOD has been previously implicated in acute and chronic lung injuries.  In two 
models of lung injury, a decrease in EC-SOD protein levels in lung extracellular matrix was 
reported by our laboratory (207, 208).  This is associated with an increase in the proteolyzed 
form of EC-SOD lacking the heparin-binding domain in both the lung and bronchoalveolar 
lavage fluid (BALF) (207).  These results suggest that increased proteolysis of EC-SOD leads to 
its removal from the lung parenchyma, perhaps leading to increased oxidative stress in the ECM.  
The results also implicate decreases in EC-SOD expression as mRNA levels of EC-SOD 
decrease after asbestos exposure compared to controls.  In support of a protective role for EC-
SOD against lung injury, transgenic overexpression of EC-SOD or treatment with SOD mimetics 
protects against bleomycin-induced pulmonary fibrosis (120, 202), while EC-SOD knockouts are 
more susceptible (204).  
EC-SOD is depleted from lung parenchyma as early as 1 day and as late as 28 days after 
exposure to asbestos.  This depletion of EC-SOD from the parenchyma could lead to increased 
oxidative stress in the lung which could stimulate progression of the disease and was associated 
with both inflammation (1 day) and fibrosis (7-28 days).  The functional role of this depletion is 
examined directly in Chapter 7 with EC-SOD knockout mice.   
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Figure 16.  EC-SOD accumulation in the airspaces persists to 28 days. 
Western blotting was performed on equal protein amounts of BAL fluid (5 µg) from the same mice in Figure 
15.  EC-SOD is found at higher levels in BAL fluid of mice treated with asbestos at all timepoints tested. 
 
 
This depletion contrasts with the timecourse of EC-SOD removal in lung parenchyma of 
mice treated with bleomycin.  In the bleomycin model, EC-SOD is initially depleted from the 
parenchyma at 7 days but returns to normal levels at 14 days (204), and it is known that fibrosis 
regresses in this model if bleomycin is not continuously supplied (266).  Persistence of depletion 
of EC-SOD from the lung in asbestosis indicates that the asbestos model produces more chronic 
lesions than bleomycin.  Since EC-SOD is depleted from fibrotic areas of long-standing human 
IPF (see Chapter 8), asbestos may be a better model for IPF.   
The depletion of EC-SOD from lung parenchyma coincides with the accumulation of 
proteolyzed EC-SOD in the bronchoalveolar lavage fluid.  While this suggests that lung 
parenchyma EC-SOD is being cleaved and released into the BAL fluid, the possibility exists that 
inflammatory cells in the airspaces release this antioxidant.  Loss of lung parenchymal EC-SOD 
may simply be due to degradation or clearance into the circulation, or through decreased 
expression.  The source of the airspace EC-SOD is examined in greater detail in Chapter  6.   
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6. AIRSPACE INFLAMMATION AND EC-SOD 
The studies described in Chapter 5 reveal a depletion of EC-SOD from the lung parenchyma and 
an accumulation of EC-SOD in the airspaces in an asbestos-induced model of pulmonary 
fibrosis.  However, the mechanisms governing these changes in EC-SOD localization are 
unknown.  Specifically, the relative contributions of the airspace inflammation and of the 
interstitial inflammation and interstitial extracellular matrix remodeling to EC-SOD distribution 
have not yet been examined.  It was hypothesized that the depletion of EC-SOD from the lung 
parenchyma required interstitial processes that occurred in pulmonary fibrosis.  It was also 
hypothesized that the clearance of EC-SOD from the lung parenchyma led to the observed 
accumulation of this protein in the airspaces.  In order to test these hypotheses, EC-SOD was 
examined in a model of pulmonary airspace inflammation induced by the inhalation of bacteria.  
Airspace inflammation without accompanying interstitial processes would provide valuable 
insight into EC-SOD regulation in pulmonary fibrosis in which multiple airspace and interstitial 
processes are taking place. 
 
6.1. BACTERIAL INHALATION LEADS TO AIRSPACE INFLAMMATION 
K1 serotype E. coli bacteria were isolated and propagated from a patient with sepsis as described 
in Materials and Methods (see Chapter 3.1.4.1).  Wild type C57BL/6 mice were then exposed to 
the bacteria through the inhalational mode of inoculation.  These mice were euthanized at 0, 6, 
and 24 hours after exposure and parameters of lung inflammation were examined. 
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Figure 17.  Bacterial recovery from lungs of mice that have inhaled E.coli. 
C57BL/6 mice were exposed to E. coli bacteria through inhalation.  Left lungs were isolated from mice 
euthanized at three timepoints to determine initial bacterial load (0 hour), or the bacterial burden as the lung 
clears the infection (6 and 24 hours).   Data is expressed as colony forming units (cfu) formed per mL of lung 
homogenate.   
 
    Bacterial recovery from the lungs of these mice was used as an indicator of initial 
bacterial load as well as to track the clearance of bacteria from the lung.  This clearance is a 
normal part of the immunological defense against such organisms.  To determine bacterial load, 
the left lungs were isolated from mice and homogenized followed by plating of the homogenate 
on LB agar and counting of colonies after incubation.  At time 0, there is a large amount of 
bacteria in the lungs, leading to approximately 3,567 colony forming units per mL (Figure 17).  
This number decreased at 6 and 24 hours, with 700 cfu/mL at the latter timepoint.   
Histology of the lungs at 0 hours revealed normal lungs with only a few macrophages in 
the airspaces (Figure 18).  At 24 hours, the airspaces have increased numbers of inflammatory 
cells.  At greater magnification, the majority of the cells were determined to be PMN.  In spite of 
this airspace inflammation, the lung parenchyma was spared from inflammation and any 
apparent histologic changes or damage. 
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 Figure 18.  Mice exposed to bacteria have increased inflammatory cells in the airspaces. 
Hematoxylin and eosin staining was performed on lung sections from mice exposed to bacteria.  While lungs 
are normal at 0 hours (left panel), airspace inflammation typical of pneumonia appears at 24 hours (middle 
panel), and is dominated by PMN (right panel).  Note that the lung parenchyma (alveolar septa, bronchioles) 
is normal in spite of this airspace inflammation.   
 
 
 To quantify the influx of these PMNs, total cell counts, myeloperoxidase, and MMP-9 
measurements were performed.  Myeloperoxidase and MMP-9 are both enzymes produced by 
neutrophils and therefore can be used as surrogate markers for this cell (200, 274).  Total cell 
counts of PMNs in the BAL fluid revealed a significant increase at 6 and 24 hours compared to 
time 0 (Figure 19).  Further, myeloperoxidase levels showed a trend to increase at 6 and 24 
hours, and MMP-9 was significantly upregulated at 24 hours.   
Collectively, this data characterizes the airspace inflammation that results after mice are 
exposed to bacteria.  This pneumonia model shares a number of notable characteristics with the 
asbestosis/pulmonary fibrosis model described in Chapter 4, including airspace inflammation 
that is predominated by PMNs.  However, this model also differs from pulmonary fibrosis in that 
it lacks interstitial processes such as inflammation and extracellular matrix remodeling in the 
lung interstitium.  By dissociating the airspace and interstitial processes, the pneumonia model 
should provide evidence for the relative roles of these processes in the redistribution of EC-SOD 
that occurs in response to inflammatory and fibrotic injuries in the lung.   
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Figure 19.  PMN and macrophages are increased after bacterial exposure. 
PMNs and macrophages were quantitatively analyzed through direct cell counts in BAL fluid (A). 
Myeloperoxidase activity from lung homogenates (B), and gelatin zymography for MMP-9 in BAL fluid (1 
µg) (C) were assessed as surrogate markers for PMN.  Overall, these figures show an increase in 
inflammation at 6 and 24 hours after bacterial inhalation in mice.    * p < 0.05 compared to 0 h, one way 
ANOVA and Tukey’s post test.  ** p < 0.05 compared to both 0 h and 6 h, one way ANOVA and Tukey’s post 
test, *** p < 0.05, Student’s t test. 
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6.2. INFLAMMATION LEADS TO EC-SOD ACCUMULATION IN AIRSPACES 
EC-SOD levels were determined in BAL fluid of mice exposed to E. coli bacteria.  Although 
there was no significant accumulation of EC-SOD in BAL fluid at 6 hours compared to 0 hours 
(Figure 20), there was a significant increase at 24 hours (Figure 21).  The ratio of cut to uncut 
EC-SOD was also increased at 24 hours compared to time 0.  EC-SOD assay results confirmed 
our findings, as no detectable levels of EC-SOD were found for four out of five samples at 0 and 
at 6 hours, but EC-SOD activity was observed at 24 hours (Figure 22). 
 
6.3. AIRSPACE INFLAMMATION DOES NOT ALTER PARENCHYMAL EC-SOD 
Although the BAL fluid showed a similar increase in EC-SOD levels in pneumonia and in 
pulmonary fibrosis, the lung parenchymal levels were unknown.  The abundance of EC-SOD in 
the lung parenchyma was measured using western blotting.  Western blots revealed no 
significant change in lung parenchymal EC-SOD at 0, 6, or 24 hours (Figure 23).  
Immunohistochemistry was also performed to verify these results.  Lung sections at time 0 
revealed strong alveolar staining for EC-SOD (Figure 24).  Sections from mouse lungs harvested 
at 24 hours possessed a similar intensity of staining for EC-SOD.    
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Figure 20.  EC-SOD in BAL fluid is not significantly altered 0 and 6 hours after bacterial exposure. 
EC-SOD levels in BAL fluid (5 µg of each sample loaded) were determined by western blotting followed by 
densitometry.  There was no significant difference between 0 hour and 6 hour timepoints.   
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Figure 21.  EC-SOD accumulates in the BAL fluid at 24 hours post-bacterial inhalation. 
EC-SOD levels in BAL fluid (3 µg) 24 hours after inhalation of bacteria was measured by western blotting 
(A).  Densitometry showed increased EC-SOD at 24 hours compared to 0 hours (B).  The EC-SOD at 24 
hours also had an increase in cut to uncut ratio (C).  * p < 0.05, Student’s t test. 
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Figure 22.  EC-SOD Activity in BAL fluid increases 24 hours after bacteria exposure. 
EC-SOD activity was determined in BAL fluid (N=5 at each timepoint) recovered at the indicated timepoints 
after bacterial inhalation in mice.  Activity was determined through inhibition of the reduction of cytochrome 
c by the xanthine/xanthine oxidase superoxide-generating system.  At 0 and 6 hours, four out of five samples 
were below detectable levels of EC-SOD activity.  * p < 0.05, one way ANOVA and Tukey’s post test. 
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Figure 23.  EC-SOD is not depleted from the lung after bacterial exposure. 
Western blotting was performed on equivalent protein amounts of lung homogenates (8 µg) from mice 
exposed to bacteria.  Densitometry was normalized to β-actin as a loading control.  In contrast to pulmonary 
fibrosis models, total EC-SOD is unchanged in lung homogenates 24 hours after inoculation.  p = 0.15, 
Student’s t test. 
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Figure 24.  EC-SOD is not removed from lung parenchyma during airspace inflammation. 
5 µm thick paraffin embedded lung sections from mice sacrificed at 0 hours (A and C) or at 24 hours (B and 
D) after E. coli bacterial inhalation were stained with antibody against EC-SOD (1:500 dilution, A and B) or 
with normal rabbit serum (1:500, C and D).  EC-SOD labeling intensity (E) is unchanged 24 h after 
inoculation (p = 0.54, Student’s t test).  Bar equals 50 µm. 
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These results indicated that, although there was accumulation of EC-SOD in the BAL 
fluid during airspace inflammation, there was no depletion of EC-SOD from the lung 
parenchyma.  In contrast, pulmonary fibrosis models lead to depletion from lung parenchyma as 
well as accumulation in the airspace.  This indicated that the removal of EC-SOD from the 
interstitium is unique to pulmonary fibrosis, due to processes unique to that disease, and cannot 
be recapitulated with airspace inflammation alone.  
 
6.4. AIRSPACE EC-SOD ORIGINATES FROM INFLAMMATORY CELLS 
As the pneumonia experiments suggested that the EC-SOD accumulating in the airspace/BAL 
fluid does not arise from the lung parenchyma, it was hypothesized that there must be another 
source of this protein in the airspaces.  The most obvious source appeared to be the macrophages 
and neutrophils, which are known to produce EC-SOD (184).  It was hypothesized that these 
inflammatory cells release EC-SOD into the airspaces. 
Immunohistochemical staining provided evidence of an inflammatory cell origin of EC-
SOD.  When staining sections with anti-EC-SOD antibody, staining localized to neutrophils and 
macrophages in addition to alveolar epithelium (Figure 25).  However, localization of EC-SOD 
to inflammatory cells still does not prove that the antioxidant is solely arising from these cells. 
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Figure 25.  EC-SOD localized to PMN and macrophages in bacterial pneumonia. 
Immunohistochemical staining was performed with anti-mouse EC-SOD antibody as in Figure 24.  PMN and 
macrophages both stained strongly for EC-SOD.  Bar equals 50 µm. 
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Figure 26.  Airspace EC-SOD originates from outside the lung in asbestosis.   
Western blots for EC-SOD were performed on equal protein loaded lung homogenates (A) and BAL fluid (10 
µg) (B) from SPC EC-SOD transgenic (Tg) and wild type (WT) mice.  A)  Tg mice produce both the human 
and mouse forms of EC-SOD (distinguishable on reducing SDS-PAGE) in the lung while inflammatory cells 
express only mouse EC-SOD.  B)  14 days after exposure to an inflammatory stimulus (asbestos), there is 
BAL fluid accumulation of only mouse EC-SOD in the Tg mice, suggesting an extrapulmonary source of EC-
SOD (i.e. infiltrating inflammatory cells).   
 
 
79 
 To further examine the role of inflammatory cells in airspace EC-SOD accumulation, 
experiments were performed with a strain of transgenic mice possessing lung-specific expression 
of human EC-SOD.  These mice possess the gene for human EC-SOD under the lung-specific 
surfactant protein C (SPC) promoter and have been described previously (197).  Inflammatory 
cells and all other tissues produce only mouse EC-SOD, and the human and mouse EC-SOD can 
be distinguished on reducing SDS-PAGE by size. 
Transgenic mice and wild type littermates were exposed to saline or to asbestos fibers by 
intratracheal instillation and sacrificed at 14 days.  This is a timepoint at which it is known that 
EC-SOD is depleted from the lung and accumulates in the BAL fluid after asbestos exposure 
(see Figure 15).  Western blotting for human and mouse EC-SOD was performed with an 
antibody that detects both human and mouse forms.  In the lung homogenates from saline-treated 
mice, both human and mouse EC-SOD are detected in the transgenic mice, while only the mouse 
form is present in wild types (Figure 26).   
In the BAL fluid of mice treated with asbestos, only the mouse form of EC-SOD is 
observed (Figure 26).  This indicated that lung EC-SOD is not released into the airspaces in 
pulmonary fibrosis.  Instead, the airspace accumulation of this antioxidant is most likely due to 
release from cells originating outside of the lung.  In this case, these cells are macrophages and 
PMNs.  In this experiment, however, we cannot rule out the possibility that only mouse EC-SOD 
from the lung, but not human EC-SOD from the lung, is being redistributed to the airspace.  This 
would be extremely unlikely due to the presence of the heparin-binding domain in both human 
and mouse EC-SOD.  
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6.5. CONCLUSIONS 
Proteolytic processing of the heparin-binding domain of EC-SOD, accompanied by depletion of 
this antioxidant from the lung parenchyma and accumulation in the airspaces, was observed in 
bleomycin- (207) and asbestos- (see Chapter 5) mediated lung disease.  A similar depletion from 
the lungs was observed in response to hyperoxia (208).  Since these disease processes are 
characterized by interstitial inflammation and remodeling, we hypothesized that these interstitial 
processes are responsible for the proteolysis and redistribution of EC-SOD.  To test this 
hypothesis, we examined the proteolysis and localization of EC-SOD in a bacterial 
pneumonia/bacterial clearance model which lacks interstitial remodeling events and in which 
inflammation is limited to the airspaces.  
As expected, our studies show that challenge of mice with inhaled E. coli bacteria leads 
to an inflammatory reaction 6 and 24 h later that is localized primarily to the airspaces.  PMN 
leukocytes in particular were increased, as determined by histology, BAL fluid cell counts, 
myeloperoxidase, and MMP-9 activity.  Notably, this neutrophilic influx is also observed in 
asbestos-induced interstitial lung disease. 
We also found a significant increase in EC-SOD levels in the airspaces at 24 h, as 
measured in the BAL fluid.  This accumulation is similar to that seen in the asbestos mouse 
model (see Chapter 5).  However, in contrast to findings in interstitial lung diseases which show 
a loss of EC-SOD from the lung parenchyma, lung homogenates and immunohistochemistry did 
not show any change in EC-SOD in the lung parenchyma following bacterial pneumonia, in 
which the inflammatory response is limited to the airspaces.   
Pulmonary fibrosis disease models have effects on both the interstitium (inflammation 
and either fibrosis or interstitial thickening) and the airspaces (inflammation).  In contrast, 
bacterial pneumonias cause inflammation primarily in the airspaces.  This difference may 
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underlie the lack of EC-SOD depletion from the lung parenchyma in bacteria-exposed mice.  
Interstitial inflammation or remodeling processes may lead to the elaboration of proteases that 
cleave the heparin-binding domain of EC-SOD in the lung parenchyma.  Without a significant 
interstitial component to the disease, as in the pneumonia model, EC-SOD remains at normal 
levels in the lung parenchyma.   
Notably, we observed EC-SOD accumulation in the airspaces during bacterial pneumonia 
in spite of the retention of EC-SOD in the lung parenchyma.  This suggests that proteolysis and 
diffusion of EC-SOD from the matrix into the airspaces is not the source of EC-SOD that 
accumulates in alveolar lining fluid.  As PMNs and macrophages are present in the airspaces in 
both interstitial lung diseases and pneumonia, and these cells possess large amounts of EC-SOD 
(184, 275), we hypothesized that these cells may be the source of the EC-SOD accumulation in 
airspaces after inflammatory injuries in the lung.  We did observe that although neutrophils are 
significantly increased at 6 h, significant EC-SOD accumulation in BAL fluid does not occur 
until 24 h.  It is likely that a period of time is required to accumulate enough EC-SOD to detect 
by western blotting and the activity assay.  We also cannot rule out a role for macrophages, since 
they are significantly elevated at 24 h but not at 6 h.  However, the large influx of neutrophils 
compared to macrophages implies a greater neutrophilic contribution to airspace EC-SOD. 
In experiments with transgenic mice producing human and mouse EC-SOD in the lung 
and only mouse EC-SOD in all other cells and tissues, we found only mouse EC-SOD in the 
BAL fluid after a stimulus for inflammation and interstitial lung injury.  This finding strongly 
suggests that inflammatory cells transport and release EC-SOD into the airspaces since a lung 
origin would lead to both human and mouse isoforms in the airspace.  Other authors have 
suggested a role for neutrophils and macrophages in transporting EC-SOD into the lung (184).  
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However, we cannot rule out the less likely possibility that only mouse EC-SOD, but not human 
EC-SOD, is being redistributed to the airspace.   
It is not yet known whether this increased EC-SOD in the BAL fluid represents a 
protective response.  Proteolyzed EC-SOD retains its catalytic antioxidant capacity.  Its release 
in sites of PMN infiltration may act to balance the large pro-oxidant activities of neutrophils.  
The release of EC-SOD may act to prevent widespread oxidative damage to alveolar airspace 
contents such as surfactant and epithelial cells.  EC-SOD is also known to inhibit neutrophil 
influx in response to hyperoxia (197), LPS (201), and bleomycin (204).  It was shown that some 
of these effects in the LPS model are mediated by alterations in cytokine production as well as 
endothelial selectins and adhesion molecules (201).  Therefore, release of EC-SOD from 
neutrophils may serve as a mechanism to limit further neutrophil influx.   
In conclusion, EC-SOD accumulates in the BAL fluid of mice following inhaled E. coli 
challenge.  This is not accompanied by any depletion of EC-SOD from the lung parenchyma, 
indicating that PMN leukocytes and macrophages release this antioxidant into the airspaces.  
This pattern differs from that seen in interstitial lung diseases, where the presence of interstitial 
inflammation and remodeling may contribute to the depletion of EC-SOD from the pulmonary 
interstitium.  Our data suggests differential regulation of this antioxidant in the progression of 
interstitial lung disease and bacterial pneumonia and that inflammatory cells are a source of 
airspace EC-SOD during pulmonary inflammatory responses. 
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7. EC-SOD KNOCKOUT MICE HAVE INCREASED SUSCEPTIBILITY TO 
ASBESTOS 
Chapter 5 described the loss of EC-SOD from lung parenchyma after exposure to asbestos at 
both acute and chronic timepoints.  Studies described in Chapters 5 and 6 demonstrated that this 
depletion is an event unique to pulmonary fibrosis likely due to interstitial processes occurring in 
that disease.  Also, it was found that airspace EC-SOD can accumulate due to apparent release of 
the antioxidant from inflammatory cells.  However, these studies did not directly examine the 
role of EC-SOD in the development of asbestosis.  We hypothesized that EC-SOD has a 
protective effect on the lung and that its absence would lead to greater disease severity.  
Therefore, we examined asbestosis in mice that are null for the EC-SOD gene and do not 
produce any of this antioxidant.   
 
7.1. EC-SOD KNOCKOUT MICE DEVELOP WORSE INFLAMMATION 
Wild type and EC-SOD knockout mice were exposed to asbestos via intratracheal instillation and 
sacrificed at 1 and 28 days.  BAL fluid from these mice revealed significantly increased BAL 
fluid protein in the knockout/asbestos mice versus the wild type/asbestos mice, indicating greater 
damage in the knockout mice (Figure 27).  Inflammation was also increased, as neutrophil counts 
in the BAL fluid were also increased in the knockout mice (Figure 28).  This data showed that 
the inflammatory response to asbestos is heightened when EC-SOD is not present in the lung.   
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Figure 27.  EC-SOD knockout mice have increased BAL fluid protein. 
BAL fluid was recovered from mice intratracheally instilled with 0.1 mg crocidolite asbestos.  Protein content 
was determined with the Coomassie Plus Protein Assay Reagent.  Mice that do not express EC-SOD possess a 
greater amount of protein in their airspaces after asbestos instillation.  * p < 0.05 Student’s t test. 
 
 
 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1 d 28 d
to
ta
l B
A
L 
flu
id
 c
el
ls
 (x
10
6 ) WT
KO
*
*
to
ta
l B
A
L 
flu
id
 c
el
ls
 (x
10
6 )
 
Figure 28.  EC-SOD knockout mice have increased PMNs. 
BAL fluid was recovered 1 or 28 days after asbestos instillation.  Total cell counts were taken and differential 
counts performed on BAL fluid spun onto slides with a cytospin.  Percentages of PMNs were multiplied by 
the total number of cells to get total PMN numbers in BAL fluid.  EC-SOD knockout mice displayed greater 
PMN influx than the wild types.  
* p< 0.05 Student’s t test. 
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7.2. EC-SOD KNOCKOUT MICE DEVELOP WORSE FIBROSIS 
To determine levels of fibrosis in EC-SOD knockout mice exposed to asbestos, histology and 
hydroxyproline analysis were undertaken.  Histology revealed an increase in fibrosis at 28 days 
in knockout versus wild type mice when both were treated with asbestos (Figure 29).  The 
pathology grade was significantly increased in the knockout mice over wild type mice.  
Hydroxyproline levels from lungs of EC-SOD knockout mice also confirmed these findings of 
increased fibrosis (Figure 30). 
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Figure 29.  EC-SOD knockout mice exhibit worsened fibrosis after asbestos. 
Wild type and EC-SOD knockout mice were euthanized 28 days after intratracheal administration of 0.1mg 
crocidolite asbestos.  Histologically, hematoxylin and eosin staining revealed greater lung fibrosis in knockout 
mice (B) compared to wild types (A).  Pathology index scores were assigned by a blinded pathologist (T.D.O.) 
and also indicated increased fibrosis in knockouts (C).  Scoring: 0=no fibrosis, 1=0-25% fibrosis, 2=25-50%, 
3=50-75%, 4=75-100%.  * p < 0.05, Student’s t test. 
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Figure 30.  EC-SOD knockout mice have increased hydroxyproline levels at 28 days. 
Mice were treated as Figure 29.  After 28 days, mice were euthanized and lungs recovered.  The lungs were 
acid hydrolyzed and hydroxyproline levels were determined as a measure of fibrosis.   
* p < 0.05, Student’s t test. 
 
7.3. CONCLUSIONS 
In Chapter 5, an alteration in EC-SOD localization was described after asbestos exposure 
in mice that involved a depletion of EC-SOD from lung parenchyma.  Although removal from 
the lung would suggest that the lung would be more susceptible to increased oxidative stress and 
injury, it was not known whether this was the case.  To definitely test the role of EC-SOD in the 
development of asbestosis, we examined EC-SOD knockout mice in our model system.  It was 
hypothesized that EC-SOD knockout mice would develop worse disease in response to asbestos 
compared to wild type mice. 
EC-SOD knockout mice were examined at 24 hours and 28 days post-asbestos exposure.  
BAL fluid revealed increased parameters of lung injury, as higher protein levels and PMNs 
accumulated in the airspaces of knockout mice compared to wild type mice.  Knockout mice also 
exhibited greater levels of fibrosis as determined by histologic scoring and hydroxyproline 
analysis.    
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These results indicate that EC-SOD plays an important protective role in asbestos-
induced pulmonary fibrosis.  Both inflammation and fibrosis were increased when EC-SOD was 
absent from the lung, suggesting that our findings of depleted lung parenchymal EC-SOD from 
wild type mouse lungs after asbestos is in fact detrimental in this disease.  It also suggests that 
the airspace accumulation of EC-SOD may also be protective, as the knockout mice would also 
not exhibit this accumulation.  As discussed in Chapter 6.5, EC-SOD release from inflammatory 
cells could prevent further inflammation.  The two fold effect of depletion from lung 
parenchyma and loss of airspace EC-SOD probably underlies the increased susceptibility of 
knockout mice to asbestos lung disease. 
The targets of increased oxidative stress resulting from loss of EC-SOD remain to be 
determined.  Matrix metalloproteinases are a potential target of oxidative stress because of their 
propensity to become activated after ROS exposure (229, 231, 276).  The activity of these 
proteases is examined in Chapters 9 and 10.  Collagen is another potential target of oxidative 
stress in asbestos lung injury and is present in high amounts in the extracellular matrix.  Collagen 
fragments are known chemoattractants and activators of neutrophils (205, 206).  Not only can 
ROS activate MMPs which cleave collagen (229, 231, 276), collagen itself can be directly 
fragmented by oxidative stress (277).  EC-SOD has been shown to associate with type I collagen 
and can prevent its oxidative fragmentation in vitro (174) and in vivo (204).  Depletion of EC-
SOD from the lung parenchyma could lead to increased collagen fragmentation and increased 
neutrophil chemotaxis and activation.  It has already been shown that EC-SOD can inhibit 
pulmonary inflammation in response to hyperoxia (197) and bleomycin (204).  In further support 
of this hypothesis, it was found that neutrophil immigration into the lung coincides with loss of 
EC-SOD from the lung in asbestos-treated mice (see Figure 5, Figure 11, and Figure 15).  
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Neutrophils themselves can also produce large quantities of reactive oxygen species (which can 
lead to more collagen fragmentation) and proteases (which can cleave collagen and can also 
potentially cleave the heparin-binding domain of EC-SOD, leading to its release from the lung 
parenchyma) (115, 278).  
Overall, loss of EC-SOD in asbestosis is likely to contribute to pathogenesis of the 
asbestosis and pulmonary fibrosis in general.  Greater understanding of the targets of increased 
oxidative stress in the lung will greatly aid development of new therapies for the disease.  
Furthermore, treatment of patients with antioxidant therapy may improve symptoms and 
outcomes.    
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8. EC-SOD IN HUMAN IDIOPATHIC PULMONARY FIBROSIS 
Although the results presented thus far indicate an important role for EC-SOD in the 
pathogenesis of experimentally-induced pulmonary fibrosis, it is unclear whether EC-SOD is 
involved in the development of human idiopathic pulmonary fibrosis.  We examined lung tissue 
samples taken from IPF patients for the presence of EC-SOD, hypothesizing that patients with 
IPF had less EC-SOD in the lung than normal patient controls. 
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Figure 31.  Technique for determination of EC-SOD levels in IPF lung. 
To quantify the amount of EC-SOD in fibrotic versus normal regions of IPF lung, slides were cut from frozen 
blocks to identify these areas.  Using this as a guide, the frozen blocks were dissected and normal and fibrotic 
areas isolated and homogenized separately.   
 
 EC-SOD was assessed via western blot analysis using both normal and IPF lung tissue 
homogenates.  All lungs, normal and IPF, showed a large variability in the amount of EC-SOD 
isolated.  We attempted a different analysis to correct for this variability.  Instead of comparing 
normal controls versus IPF patients, we compared normal and fibrotic regions from the same IPF 
patient.  After identifying these regions microscopically from sections cut from frozen blocks, 
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these regions were dissected from the blocks (Figure 31).  The separate pieces were then 
individually homogenized and analyzed on western blots.  As shown in Figure 32, when 
comparing normal and fibrotic areas from the same lung, EC-SOD was depleted in the fibrotic 
areas.   
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Figure 32.  Fibrotic lung has less EC-SOD than normal lung from the same IPF patient. 
Tissue homogenates isolated as described in Figure 31 were equal protein amounts (10 µg) subjected to SDS-
PAGE and western blotting for EC-SOD.  Samples from four IPF patients are shown (#1-4).  The adjacent 
normal (N) and fibrotic (F) regions of the lung were compared.  Densitometry was expressed as percent of 
normal, with normal equaling 100%.  Fibrotic lung regions showed a decrease in EC-SOD levels.   
* p < 0.05, Student’s t test. 
 
 In collaboration with the laboratory of Vuokko Kinnula in Finland, 
immunohistochemistry was performed on sections from paraffin-embedded UIP patients.  
Immunohistochemical staining for EC-SOD in UIP lungs showed positive labeling in normal 
alveolar parenchyma that was noticeably absent from fibrotic areas of the lung.  This data is 
consistent with our western blot findings in Figure 32.   
91 
8.1. CONCLUSIONS 
Our results in IPF tissue samples show that similar events occur in both experimentally-induced 
and human pulmonary fibrosis.  Namely, EC-SOD is depleted from the lung parenchyma during 
the development of pulmonary fibrosis in mice, and EC-SOD is also depleted from fibrotic lung 
in IPF patients in comparison to adjacent normal tissue.  Loss of EC-SOD from these regions 
could contribute to an oxidant/antioxidant imbalance in the lung parenchyma.  Potential targets 
of increased oxidative stress have already been discussed in Chapter 7.3, and the resulting 
damage could contribute to the development of fibrosis.  Our data shows that there is less EC-
SOD in the lung once fibrosis has developed.  In theory, antioxidant therapy may reduce 
oxidative stress in fibrotic areas of the lung, and, more importantly supplement the EC-SOD 
already found in the normal areas of lung.  This may help to limit progression of the disease by 
limiting oxidative stress and preventing normal lung development of fibrosis.    
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9. MATRIX METALLOPROTEINASES IN ASBESTOSIS 
It is widely recognized that MMPs play an important role in normal and diseased lung (279).  
Their upregulation has been noted in a number of pulmonary conditions including bleomycin-
induced and silica-induced pulmonary fibrosis (33, 261).  However, the regulation of MMPs in 
asbestosis has not been examined previously.  Furthermore, the relationships between oxidative 
stress, EC-SOD, and MMPs have not been specifically studied in any of the pulmonary fibrosis 
diseases.  Therefore, we examined the levels and role of MMPs as well as their endogenous 
TIMP inhibitors in our asbestos-induced disease model.   
 
9.1. MMP-2 AND MMP-9 ARE UPREGULATED IN ASBESTOSIS 
MMP-2 and -9, also known as gelatinase A and B, respectively, were studied in our mouse 
model of pulmonary fibrosis.  These two MMPs are thought to be involved in the development 
of pulmonary fibrosis because of their high expression in other lung diseases and because of their 
ability to degrade native type IV collagen (236).  Since one of the earliest steps in the 
pathogenesis of this disease is the loss of epithelial barrier integrity (280) and since the 
epithelium lies upon the basement membrane rich in collagen type IV, the gelatinases could play 
an important role in degradation of this barrier.  We hypothesized that MMP-2 and -9 would be 
upregulated in asbestosis.  
 A common technique used to study these two MMPs is gelatin zymography.  
Zymography is an SDS-PAGE technique in which gelatin is incorporated into the electrophoretic 
gel during its casting (272).  Samples containing MMPs are electrophoresed under nonreducing 
denaturing conditions.  After electrophoresis, the denaturing agent (SDS) is removed, activity is 
restored, and the MMPs are able to cleave the gelatin in the gel.  Coomassie staining of the gel 
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after an incubation period reveals the location of MMPs as clear zones against a blue 
background.  This technique allows for the quantification of both MMP-2 and MMP-9, as well as 
active versus latent forms, as these species migrate differently on SDS-PAGE.  Zymograms are a 
better method than western blots because sensitivity is greater, generally in the picomolar range 
(281).  Lung homogenates on zymograms typically show three major bands in the molecular 
weight region of MMP-2 and MMP-9.  The 105kD band represents the latent form of MMP-9 
while the active form is undetectable.  Latent MMP-2 is approximately 72kD while active MMP-
2 is 62kD, reflecting cleavage of the prodomain.   
 Figure 33 shows a zymogram containing equal protein amounts of lung homogenates 
from titanium dioxide-treated controls and mice euthanized at 1, 7, 14, and 28 days after 
intratracheal instillation of asbestos.  The zymogram shown is representative of a larger sample 
set, and densitometry was performed on 3 to 6 samples for each group at each timepoint.  The 
asbestos values were all normalized to the titanium dioxide-treated controls at that timepoint, so 
that control values always equaled one.   
 In lung homogenates, the two gelatinases show different kinetics of upregulation.  MMP-
9 has its greatest increase over control values acutely at 1 day and then returns to baseline at all 
other timepoints.  In contrast, protein levels of MMP-2, particularly active MMP-2, are increased 
more chronically, beginning at 1 day but persisting even at 28 days with a peak at 7 and 14 days.  
The ratio of active to latent MMP-2 was also significantly increased at all timepoints due to the 
increase in active MMP-2.  The identity of these bands as MMPs was confirmed because 
incubation of the gel with the zinc chelator, 1,10-phenanthroline, inhibited development of these 
bands. 
94 
Lung MMP-9
0.0
0.3
0.5
0.8
1.0
1.3
1.5
1 d 7 d 14 d 28 d
de
ns
ito
m
et
ry
 
as
be
st
os
 / 
Ti
O
2 *
Lung Latent MMP-2
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
1 d 7 d 14 d 28 d
de
ns
ito
m
et
ry
 
as
be
st
os
 / 
Ti
O
2
*
*
*
Lung Active MMP-2
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
1 d 7 d 14 d 28 d
de
ns
ito
m
et
ry
 
as
be
st
os
 / 
Ti
O
2
*
*
*
*
de
ns
ito
m
et
ry
 
as
be
st
os
 / 
Ti
O
2
de
ns
ito
m
et
ry
 
as
be
st
os
 / 
Ti
O
2
de
ns
ito
m
et
ry
 
as
be
st
os
 / 
Ti
O
2
de
ns
ito
m
et
ry
 
as
be
st
os
 / 
Ti
O
2
de
ns
ito
m
et
ry
 
as
be
st
os
 / 
Ti
O
2
de
ns
ito
m
et
ry
 
as
be
st
os
 / 
Ti
O
2
 
Figure 33.   MMP-2 and MMP-9 are increased in lung homogenates after asbestos. 
Wild type C57BL/6 mice were exposed to asbestos and euthanized at 1, 7, 14, and 28 days.  Gelatin 
zymography of CHAPS-extracted (10 mM) lung homogenates (equal loading, 15 µg) was performed.  A 
representative gel is shown but densitometry was performed on zymograms comparing controls and asbestos 
samples at each timepoint (N=3-6).  Densitometry was normalized as the average intensity of the asbestos 
bands divided by the average of the control (titanium dioxide) bands at the same timepoint.  The 
identification of bands as MMP-2 and MMP-9 was made through comparison with purified MMP-2 and 
MMP-9 (+).  Latent and active MMP-2 are increased at all timepoints, while MMP-9 is significantly increased 
at 24 h only.  *P<0.05 Student’s t test, comparing asbestos to control at each timepoint. 
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 BAL fluid samples from the same control and asbestos mice described above were also 
subjected to gelatin zymography (Figure 34).  In the BAL fluid, latent MMP-9 and only the 
latent form of MMP-2 could be detected.  While MMPs were nearly undetectable in control 
mice, MMP-2 and MMP-9 were significantly elevated at all timepoints following asbestos 
exposure.  As in the lung, MMP-9 levels were particularly high at 1 day although titanium 
treatment also increased MMP-9 at this time, leading to a lower than expected ratio between 
asbestos to titanium.  The highest MMP-2 levels were noted at 1-14 days.  Overall, gelatin 
zymography revealed that MMP-9 is predominantly increased at 1 day, while MMP-2 has a more 
protracted increase in lung parenchyma and alveolar lining fluid after asbestos exposure. 
Localization of these MMPs in asbestosis was determined through the use of 
immunohistochemistry.  Although zymography can be adapted to detect gelatinase activity in 
lung sections, immunohistochemistry with separate antibodies for MMP-2 and MMP-9 allowed 
us to differentiate between the two gelatinases.  
As we described previously, asbestos-exposed mice revealed neutrophilic influx and 
some edema and interstitial thickening at 1 day, followed by progressively worsening fibrosis at 
7, 14, and 28 days (see Chapter 4).  In the context of these histologic changes, we observed the 
most intense staining for MMP-9 at 1 day, and this was localized to the bronchiolar airspaces of 
asbestos-treated mice but not titanium dioxide-treated mice (Figure 35).  Staining was associated 
with neutrophils aggregating around asbestos fibers.  There was no observable increase in MMP-
9 staining in alveolar septa of the asbestos-treated mice at any of the timepoints, although 
occasional MMP-9 staining was observed in airspaces at 7-28 days, again associated with 
bronchiolar neutrophils.  This localization likely accounts for the transient increase at 1 day of 
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MMP-9 in lung homogenates and the more persistent expression of MMP-9 in BAL fluid as 
detected by zymography.   
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Figure 34.  BAL fluid MMPs were increased after asbestos treatment. 
MMP-2 and MMP-9 are increased in bronchoalveolar lavage (BAL) fluid after asbestos exposure.  Gelatin 
zymography and densitometry was performed as in figure 1 on equal protein amounts of BAL fluid (5 µg).  
Only the latent forms of MMP-2 and MMP-9 were found in BAL fluid.  There are significant increases in 
MMP-9 (B) and MMP-2 (C) at all timepoints following asbestos exposure.  * p < 0.05, Student’s t test, 
comparing asbestos and control. 
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Figure 35.  MMP-9 immunohistochemistry in asbestos-exposed mouse lungs. 
Mouse lungs were inflation fixed in formalin at 1, 7, 14, and 28 days after intratracheal instillation of 0.1 mg  
asbestos.  Sections were incubated with anti-MMP-9 antibody (A-C, E) from R&D Systems or with normal 
IgG as a negative control (D,F).   Line equals 50 µm. 
 (A,B) One day after asbestos exposure, bronchiolar neutrophils surrounding visible asbestos fibers (fibers at 
arrows) stained strongly for MMP-9 (red color).   
(C) Bronchiolar neutrophils retained MMP-9 positive staining at 14 d.  However, no interstitial MMP-9 was 
observed, either in normal alveolar septa or in areas of fibrosis (asterisk).  Identical staining patterns were 
observed at 7 and 28 d.   
(D) Titanium dioxide-treated mice did not display any MMP-9 staining. Macrophages that have engulfed 
these particles are clearly visible.   
(E, F) Normal goat IgG revealed no staining at 24 hours (E) or 14 days (F) or at any timepoint.   
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Figure 36.  MMP-2 immunohistochemistry in asbestos-exposed mouse lung. 
Sections were incubated with anti-MMP-2 antibody (R&D Systems) as described in Materials and Methods.  
Line equals 50 µm. 
(A) Titanium dioxide-treated mice exhibited punctuate localization of MMP-2 in type II epithelial cells 
(arrowheads).   
(B) At 1 d, asbestos-treated mice exhibited the same type II staining but in addition had a more diffuse 
staining over alveolar septa (arrows).   
(C) Also at 1 d, asbestos-treated mice had MMP-2 around bronchiolar neutrophils.   
(D) After 7 d, there is a significant increase in interstitial MMP-2 in areas of fibrosis.   
(E) As late as 28 d, fibrotic regions retain MMP-2 expression, here in fibrosis with visible asbestos fibers 
(arrows).   
(F)  Nonimmune IgG revealed no staining.   
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While titanium dioxide-treated mice exhibited punctuate intracellular staining for MMP-2 
localizing to type II epithelial cells and bronchiolar epithelium, asbestos-treated mice exhibited a 
more diffuse and often extracellular localization over alveolar surfaces (Figure 36).  MMP-2 also 
had a more protracted expression pattern, as it was located in both normal alveoli and 
particularly in fibrotic areas of lung at 7, 14, and 28 days.  MMP-2 also localized to areas 
showing inflammation, as was seen for MMP-9.  This localization corroborates our findings 
from gelatin zymography showing that MMP-2 is more predominant during development of 
fibrosis in the lung. 
 
9.2. TIMPs ARE UPREGULATED IN ASBESTOS-EXPOSED LUNGS 
The tissue inhibitors of metalloproteinases (TIMPs) are endogenous antiproteases directed 
against MMPs.  While other functions for TIMPs are being identified, it is clear that these TIMPs 
have the ability to potently inhibit, and in some cases, activate MMPs through binding in 1:1 
stoichiometry.  Analysis of their abundance is therefore important when considering MMP 
activity.  TIMP-1 and TIMP-2 are known to associate strongly with and inhibit MMP-9 and 
MMP-2, respectively.  However, these TIMPs are not limited to these MMPs, and it is important 
to note that in the right local concentrations, TIMPs can essentially inhibit any MMP. 
 Lung homogenates from asbestos-exposed mice were subjected to western blotting for 
TIMP-1 and TIMP-2.  Levels of both inhibitors increased over the timecourse of asbestos 
treatment (Figure 37).  This may indicate a role in compensating for the increased gelatinases 
found in asbestosis.  However, it may also indicate that these TIMPs are inhibiting the activity of 
other collagenases.  The TIMP upregulation could therefore skew the profibrotic/antifibrotic 
balance towards the deposition of collagen.   
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Figure 37.  TIMP-1 and -2 are increased after asbestos exposure. 
Western blotting was performed on soluble fraction (non-CHAPS-containing) lung homogenates (10 µg) from 
mice exposed to asbestos fibers.  TIMP-1 (1:1,000 antibody dilution, purchased from Triple Point Biologics), 
TIMP-2 (1:200, Chemicon), and beta-actin (1:5,000, Sigma) were all probed from the same blot.  * p < 0.05, 
one way ANOVA and Tukey’s post test.   
 
9.3. MMP INHIBITION ATTENUATES ASBESTOSIS 
The drug GM6001 has been used in vivo by other investigators and was notably shown to inhibit 
both MMP activity and disease development in murine models of asthma (282) and emphysema 
(283).  GM6001 is a reversible hydroxamic acid-based global MMP inhibitor.  GM6001 was 
intraperitoneally injected (0.2 mg per mouse, ~8.8 mg/kg) every day over the course of 14 days, 
beginning on day 0.  Mice were intratracheally instilled with asbestos on day 1 and sacrificed on 
day 13. 
 Daily doses of MMP inhibitor reduced the inflammation and lung damage found 13 days 
after asbestos.  Although BAL fluid protein was not significantly different between 
asbestos/vehicle and asbestos/GM6001 mice, the mice with MMP inhibition did have a trend 
towards less protein in the BAL (Figure 38).  Notably, while mice treated with asbestos had 
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significant elevations in the number of inflammatory cells in the BAL fluid, this inflammatory 
response was attenuated in asbestos-exposed mice treated with the MMP inhibitor (Figure 39).  
Differentials were performed on BAL fluid cytospins and revealed a significant increase in PMN 
in all asbestos-treated mice (Figure 40).  Macrophages, on the other hand, were significantly 
decreased in all of these mice.  However, the increase in PMN in the asbestos/GM6001 group is 
significantly attenuated in the airspaces of asbestos/GM6001 mice versus the asbestos/vehicle 
group.   
MMP inhibition also ameliorated the development of pulmonary fibrosis.  Measurements 
of total hydroxyproline were used as an indicator of collagen deposition in the lungs of mice 
treated with asbestos.  Although both the asbestos/vehicle and asbestos/GM6001 groups 
exhibited significant increases in fibrosis compared to titanium controls, the asbestos/GM6001 
group had a significant reduction (15%) in fibrosis compared to asbestos/vehicle (P<0.01, 
ANOVA with Tukey’s post-test) (Figure 41).  Therefore, inhibition of MMPs leads to a 
reduction in both inflammation and fibrosis in our experimental model of asbestosis. 
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Figure 38.  BAL fluid protein accumulation shows a trend to decrease after MMP inhibition. 
Wild type mice were injected daily (i.p.) with vehicle (veh) or the broad-spectrum MMP inhibitor GM6001 
beginning on day 0.  Mice were exposed to asbestos (Asb) on day 1 and euthanized on day 13.  BAL fluid 
protein was determined and found to be significantly increased over titanium controls in all asbestos treated 
mice, regardless of MMP inhibition.  However, BAL fluid from the MMP inhibited mice had a trend towards 
lower protein accumulation.  * p < 0.05 compared to TiO2 + vehicle group, one way ANOVA with Tukey’s 
post test.   
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Figure 39.  MMP inhibition reduces BAL fluid total cells after asbestos. 
Mice were treated as in Figure 38.  Although total BAL fluid cells in asbestos + vehicle group was increased 
compared to the titanium control, the cell counts were not significantly increased in the asbestos + GM6001 
group compared to TiO2 + vehicle controls.  * p < 0.05, one way ANOVA with Tukey’s post test. 
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Figure 40.  MMP inhibition reduces PMN numbers in BAL fluid. 
Differentials counts of BAL fluid total cells were performed to determine total numbers of white blood cell 
types in the lung airspaces.  Lymphocytes are shown on a separate graph due to their low overall numbers.  
After asbestos, macrophages are significantly decreased.  PMNs and lymphocytes are increased in all mice 
treated with asbestos, but this increase is attenuated in MMP-inhibited mice.  * p < 0.05, one way ANOVA 
and Tukey’s post test. 
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Figure 41.  MMP inhibition attenuates fibrosis. 
Mice were treated as in Figure 38.   Lungs were recovered, acid hydrolyzed, and hydroxyproline analysis was 
performed on the hydrolysates.  Values were expressed as % of control, with the TiO2 + vehicle controls 
equaling 100%.  Daily injections of GM6001 significantly reduced fibrosis development at 13 days.  * p < 0.05, 
one way ANOVA, Tukey’s post test. 
 
9.4. CONCLUSIONS 
Matrix metalloproteinases (MMPs) have been implicated in both human idiopathic pulmonary 
fibrosis (76) and experimental models of pulmonary fibrosis, including bleomycin- (33) and 
silica-induced models (261).  However, the MMPs have never been studied in the context of 
asbestosis.  Previous in vivo studies utilized the less fibrogenic chrysotile fibers instead of 
amphiboles, and these investigators did not observe any fibrosis at 4 weeks (260).  These studies 
also did not examine protein levels, relying on mRNA analysis instead.  In this study, we sought 
to determine whether MMPs are increased in response to a single intratracheal instillation of 
amphibole (crocidolite) asbestos and what the role of MMPs are in the development of 
asbestosis.   
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We here describe increases in MMP-2 and MMP-9 after crocidolite asbestos instillation.  
MMP-9 was increased in lung homogenates only at day 1, but latent and active MMP-2 was 
increased over all timepoints (Figure 33).  Importantly, the increase in active MMP-2 was 
particularly large at 7, 14, and 28 days, indicating potential for high proteolytic activity due to 
this MMP during the chronic fibrosis phase of this model.  The latent forms of MMP-2 and -9 
were also increased in airspaces, as sampled by BAL fluid (Figure 34).  As in the lung 
homogenates, the most profound increase in MMP-9 was at day 1 while MMP-2 remained high 
after this timepoint.   
Immunohistochemistry supported these results, as the strongest MMP-9 staining was 
found 1 day after asbestos while MMP-2 had a more protracted expression pattern (Figure 35).  
The MMP-9 localized to bronchiolar airspaces in conjunction with neutrophils and asbestos 
fibers.  Since neutrophils can express this MMP (274), it is likely that these cells are the source 
of the MMP-9.  Furthermore, it has been shown that asbestos fibers can induce the release of 
collagenases in vitro, although the collagenase was not identified (259).   
MMP-2 in control mice was expressed in a few type II epithelial cells (Figure 36).  After 
asbestos injury, staining was more diffuse over the alveolar septa, implying release from the cell.  
MMP-2 was also found in bronchiolar neutrophilic aggregates and most strikingly was observed 
throughout areas of fibrosis.  MMP-2 is kown to be expressed by fibroblasts, which may explain 
this distribution.  Furthermore, our results indicate that MMP-2 plays a significant role in the 
development of fibrosis in the lung, while MMP-9 activity appears to be important in the 
inflammatory component of the disease. 
To determine whether endogenous inhibitors were upregulated in conjunction with or as a 
compensatory response to these proteases, tissue inhibitor of metalloproteinase (TIMP) levels 
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were examined using western blotting (Figure 37).  These studies focused on TIMP-1 and TIMP-
2, which are known to most efficiently inhibit MMP-9 and MMP-2, respectively.  While these 
TIMPs were expressed at low levels in controls and at 1 day post-asbestos exposure, large 
increases in these inhibitors were found at 7 and 14 days with a lesser increase at 28 days.  Other 
investigators have found similar upregulation of TIMPs at later stages of non-asbestos models of 
fibrosis with TIMP-2 being especially highly expressed (33, 76, 257).  While it was proposed 
that TIMPs opposed the collagenolytic activity of MMPs, thus leading to a profibrotic 
environment (284), it is also possible that TIMP-2 participates in the activation of MMPs.  
TIMP-2 is known to associate with MMP-2 and lead to its activation by a separate membrane 
bound MT-MMP1 (228, 258).   
MMP inhibition has been used as an experimental therapy in animal studies of a number 
of pulmonary diseases, including asthma (282), emphysema (283), and bleomycin-induced 
pulmonary fibrosis (28).  We utilized a broad spectrum MMP inhibitor, GM6001, using daily 
intraperitoneal injections to attempt to ameliorate disease.  These studies indicate that MMP 
inhibition significantly protected against asbestos-induced lung injury by inhibiting both 
inflammation and fibrosis.   
While these results may seem counterintuitive, as MMP degradation of ECM components 
such as collagen may oppose fibrosis development, other investigators have found similar 
protection with MMP inhibition in other models of fibrosis (28).  Our findings suggest that one 
mechanism by which MMP inhibition is protective is by dampening of inflammatory responses 
to asbestos.  Based on our zymography and immunohistochemistry, inhibition of MMP-9 could 
inhibit inflammation, perhaps through reduction of basement membrane degradation and 
subsequent migration of inflammatory cells.  However, it should be noted that in the bleomycin 
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model, MMP-9 null mice were not significantly protected from fibrosis and only had an 
observed deficit in alveolar bronchiolization (219).  This does not rule out that MMP-9 activity is 
pathogenic in asbestosis as there are no published reports examining this injury in MMP-9 
knockout mice.   
On the other hand, MMP-2 was predominantly associated with fibrosis instead of 
inflammation.  Inhibition of this MMP could directly reduce the migration of fibroblasts in the 
lung and reduce fibrosis.  The role of this MMP could be studied with MMP-2 knockout mice.   
Broad spectrum MMP inhibition could exert other effects which require further studies to 
evaluate.  MMP inhibition could reduce MMP-7 activity, which is highly proinflammatory in the 
lung (29, 244).  Inhibition of MMPs could also reduce the production of collagen fragments, 
which are potent chemoattractants for neutrophils (206).  MMPs could also play a role in 
regulating the localization of the antioxidant enzyme EC-SOD, a possibility that is examined in 
further detail in Chapter 10.  Furthermore, it must be noted that GM6001 is a broad spectrum 
inhibitor, and also inhibits members of the ADAM (A Disintigrin and Metalloproteinase) family.    
In conclusion, we observed large increases in MMP-2, MMP-9, TIMP-1, and TIMP-2 in 
the course of experimentally-induced asbestosis in mice.  While MMP-9 appeared to be related 
to inflammation in the lung, MMP-2 was more strongly associated with development of fibrosis.  
MMP inhibition reduced both inflammation and fibrosis, and revealed a contributory role for 
these MMPs in antioxidant regulation.  These studies reveal a pathogenic role for MMPs in 
asbestosis and suggest a potential role in other particulate lung diseases.  These studies also 
indicate that a mechanism must exist to lead to MMP upregulation in asbestosis and other 
fibrotic lung diseases.  The role of EC-SOD in this upregulation will be evaluated in the 
following chapter. 
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10. RELATIONSHIP BETWEEN EC-SOD AND MMP UPREGULATION 
While the studies described in Chapters 5 and 9 indicate that both EC-SOD and MMPs are 
altered in either localization or abundance in asbestosis, it remains to be seen whether the events 
are directly connected.  That is, whether changes in EC-SOD affect MMPs and vice versa.  This 
question is relevant because MMPs are known to be activated by reactive oxygen species.  Since 
EC-SOD is depleted from the lungs of mice exposed to asbestos, the resulting increased 
oxidative stress could activate MMPs.  Furthermore, clearance of EC-SOD is associated with 
cleavage of the protein’s heparin binding domain.  The protease responsible for this cleavage in 
vivo in pulmonary fibrosis is unknown.  MMPs are highly upregulated in this disease and can 
therefore potentially proteolyze EC-SOD.  The colocalization of EC-SOD with collagen (172), a 
substrate for many MMPs, further strengthens this idea.  
It was hypothesized that EC-SOD and MMPs are related in function and localization in 
pulmonary fibrosis.  To examine this question, the timecourse of EC-SOD and MMP 
upregulation in both the bleomycin and asbestos models of pulmonary fibrosis were examined.  
The role that EC-SOD plays in MMP activity through the use of EC-SOD knockout mice was 
then assessed.  The role of MMPs in pulmonary EC-SOD regulation was determined with MMP 
inhibition.   
 
10.1. EC-SOD AND MMP CHANGES COINCIDE IN PULMONARY FIBROSIS 
The localization and relative levels of EC-SOD and MMPs in the asbestos model was 
described in Chapters 5 and 9, respectively.  EC-SOD is depleted from lungs beginning at 24 
hours and remains depleted until at least 28 days (Figure 12 and Figure 15).  Coincident with this 
loss is accumulation of EC-SOD in the airspaces at the same timepoints (Figure 14 and Figure 
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16).  As described in Chapter 9, MMPs are increased at the same time that these EC-SOD 
localization changes are observed.  Specifically, MMP-9 and active MMP-2 are increased at 24 
hours, with MMP-2 remaining at high levels at 7, 14, and 28 days (Figure 33 and Figure 34).  
The simultaneous occurrence of these events suggests a possible relationship between EC-SOD 
localization and MMP upregulation in asbestosis. 
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Figure 42.  Timecourse of EC-SOD depletion from the lung after bleomycin treatment. 
Western blots were performed for EC-SOD on lung homogenates (10 µg) from mice intratracheally instilled 
with saline vehicle (sal) or with bleomycin (0.06 U/mouse).  Mice were sacrificed every day for 7 days.   
Densitometry was performed and normalized to β-actin as a loading control. 
 
 
In a bleomycin model of fibrosis, the relationship between EC-SOD and MMPs was 
further examined.  In these experiments, mice were given a single intratracheal instillation of 
bleomycin and sacrificed every day for seven days.  This detailed timecourse revealed that 
depletion of EC-SOD from the lung (Figure 42) and accumulation in the BAL fluid (Figure 43) 
coincided with upregulation of MMPs (Figure 44), beginning at 3-4 days and continuing to at 
least 7 days.  The fact that these events are simultaneous in two models of pulmonary fibrosis 
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suggests that they may be related events.  Notably, PMNs were also increased at the same time 
as EC-SOD redistribution and MMP upregulation in the bleomycin model (Figure 45) and at all 
timepoints tested in the asbestos model (Figure 7) and may be the common link between these 
proteins.  As noted above, PMNs are a source of both EC-SOD and MMPs (184, 276, 285).   
 
 
Figure 43.  Timecourse of EC-SOD accumulation in BAL after bleomycin. 
Western blots were performed for EC-SOD in BAL fluid from mice treated with 0.06 U bleomycin and 
sacrificed over a 7 day timecourse.  Equal volumes (5 µL) of BAL fluid were loaded for this blot.   
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Figure 44.  Gelatinase activity in mice after exposure to bleomycin. 
Gelatin zymography was performed on CHAPS-extracted lung homogenates (30 µg) from the same mice 
described in Figure 42 and Figure 43.  While no significant changes in MMP-9 were detected, levels of active 
MMP-2 did increase beginning at day 2-3.  Densitometry data is expressed as pixel intensity of active MMP-2 
divided by intensity of latent MMP-2. 
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Figure 45.  PMNs in BAL fluid after bleomycin. 
BAL fluid was recovered from mice during a 7 day timecourse after bleomycin instillation (0.06U/mouse).  
PMNs were counted from cytospins of the BAL, and differential counts were multiplied by the total number 
of cells in the BAL to get absolute numbers of PMNs.  N=3 for each timepoint. 
 
10.2. EC-SOD KNOCKOUTS AND MMP ACTIVITY 
To definitively test whether EC-SOD is involved in the observed changes in MMPs, pulmonary 
fibrosis was induced in EC-SOD knockout mice.  EC-SOD knockout mice were examined in the 
asbestos model for MMP activity.  Using gelatin zymography as an indicator of MMP-2 and -9 
activation, no differences could be found in MMP-2 or MMP-9 at 1, 7, 14, or 28 days post 
asbestos exposure in the lung (Figure 46) or BAL fluid (Figure 47).  This does not rule out 
effects earlier than 24 hours, however, as those timepoints were not yet tested.  The largely 
negative effects of EC-SOD deficiency on MMP activity suggest that there is not a direct effect 
on these proteases by EC-SOD in asbestosis.  However, it is possible that wild type mice already 
have maximal activation of MMPs and that knockout mice cannot develop increased activation.  
More complete studies would require testing of EC-SOD transgenic overexpressors to determine 
if MMP activity is decreased.  Unfortunately, these mice were not available at the time of these 
experiments and must instead be studied in future directions. 
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 Figure 46.  Lung homogenate MMP activity in EC-SOD knockout mice treated with asbestos. 
Gelatin zymograms were performed on CHAPS detergent-extracted lung homogenates (equal protein loaded, 
15 µg) from wild type and EC-SOD knockout mice treated with 0.1 mg crocidolite asbestos and euthanized at 
the timepoints indicated.  Although MMPs increase in asbestos mice compared to titanium controls, there 
was no difference in MMP-2 or -9 levels in knockouts versus wild types when both were treated with asbestos.  
 
 
Figure 47.  BAL fluid MMP activity in EC-SOD knockout mice treated with asbestos. 
Gelatin zymograms were performed on BAL fluid (equal protein loaded, 2 µg) from wild type and EC-SOD 
knockout mice treated with 0.1 mg crocidolite asbestos and euthanized at the timepoints indicated.  No 
differences were observed in either MMP-2 or -9 comparing wild type and knockout mice treated with 
asbestos. 
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In the bleomycin model, initial studies found no difference in gelatinase activity 7 days 
after treatment in either the lungs or BAL fluid (Figure 48 and Figure 49).  However, when 
earlier timepoints were examined, a significant increase in MMP-9 was detected in BAL fluid at 
1 day in knockouts versus wild types.  This upregulation of MMP-9 was associated with an 
increase in PMN infiltration into the lung airspaces at 24 hours in knockout mice (Figure 50).  As 
PMN can produce MMP-9 (274), this shows that EC-SOD can have an indirect effect to increase 
MMP-9 levels through increases in inflammation.   
 
 
Figure 48.  EC-SOD knockout mice do not have differences in MMP activity in lung homogenates after 
bleomycin treatment  
Lungs were recovered from wild type and EC-SOD knockout mice at the times indicated after intratracheal 
bleomycin (0.06U/mouse) instillation. Gelatin zymography was performed on equal protein amounts (15 µg) 
of CHAPS-extracted lung homogenates.   No significant differences were observed or measured by 
densitometry between wild type mice and knockout mice treated with bleomycin. 
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 Figure 49.  EC-SOD knockouts have increased MMP-9 but not MMP-2 at 24 hours after bleomycin. 
Gelatin zymography was performed on equal protein amounts (5 µg) of BAL fluid recovered at the times 
indicated after intratracheal bleomycin (0.06 U/mouse) instillation.   Note the increase in MMP-9 in knockout 
mice at 1 day.  No other differences between bleomycin-treated wild types and knockouts were observed 
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Figure 50.  EC-SOD knockout mice have increased PMNs at 1 day post-bleomycin exposure. 
PMNs were counted in BAL fluid at the times indicated after bleomycin treatment (0.04 U/mouse) in wild 
type (wt) and EC-SOD knockout (ko) mice.  There are significantly more PMNs at 1 day after bleomycin in 
ko vs wt.  * p < 0.05, one-way ANOVA and Tukey’s post test comparing saline and 1 day bleomycin values. 
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10.3. MMP INHIBITION IN ASBESTOSIS  
MMPs were examined for their ability to regulate the localization of EC-SOD.  Since numerous 
MMPs could theoretically be involved in this regulation, we chose to use a broad-spectrum 
global MMP inhibitor (GM6001) in our asbestos studies.  These studies were described in 
Chapter 9.3.  Western blotting was performed for EC-SOD in the BAL fluid of mice exposed to 
asbestos with or without MMP inhibitor treatment (Figure 51).  Although EC-SOD is increased 
in the asbestos + vehicle group compared to the titanium dioxide group, there was no significant 
increase in the asbestos + GM6001 group.  The GM6001 group also displayed significant 
decreases in PMN infiltration .  Our pneumonia studies indicated that PMNs are the predominant 
source of the EC-SOD that accumulates in the airspaces (Figure 40).  Thus, these results suggest 
that MMPs regulate the localization of EC-SOD in the airspaces through reduction of PMN-
dominated inflammation after asbestos.   
 
10.4. CONCLUSIONS 
Links between EC-SOD and matrix metalloproteinases have not been previously examined, 
particularly in the case of asbestos lung injury.  It is thought that both oxidant/antioxidant and 
protease/antiprotease imbalances are involved in the development of pulmonary fibrosis.  
Reactive oxygen species can affect MMPs through oxidation of the cysteine switch in the 
proenzyme leading to activation.  Furthermore, protease/antiprotease imbalances could lead to 
the clearance of EC-SOD from lung parenchyma through proteolysis of the heparin-binding 
domain.  It was hypothesized that EC-SOD and MMPs are related in function and localization in 
pulmonary fibrosis.  These studies utilized both the asbestos- and bleomycin-models of 
pulmonary fibrosis to evaluate this possibility. 
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Figure 51.  MMP inhibition reduces airspace accumulation of EC-SOD. 
Mice were intratracheally instilled with 0.1 mg titanium dioxide or asbestos.  Concurrently, one group was 
treated with daily intraperitoneal injections of 0.2 mgGM6001, a broad spectrum MMP inhibitor, beginning 
the day before intratracheal instillation.  Mice were sacrificed at day 13 and BAL fluid collected.  EC-SOD 
was evaluated by western blotting loading equal protein amounts of BAL fluid (5 µg). The Asbestos+GM6001 
group accumulated less EC-SOD in BAL fluid than the Asbestos+Vehicle group.  * p < 0.05, one way ANOVA 
with Tukey’s post test. 
 
 
 In support of this hypothesis, it was found that the asbestos- or bleomycin-induced 
depletion of EC-SOD from the lung parenchyma in wild type mice was associated with increases 
in active MMP-2 in lung homogenates at the same time in two models of pulmonary fibrosis 
(Figure 42 and Figure 44; Figure 11, Figure 15, and Figure 33).  Loss of EC-SOD may increase 
oxidative stress in the lung and lead to oxidative activation of latent MMP-2.  Although we also 
know that EC-SOD accumulates in the airspaces, we did not observe any differences in airspace 
MMP activation.  The caveat to this finding is that in general the active MMPs are not found in 
the BAL fluid.  From these experiments in wild type animals we therefore cannot determine 
whether the airspace accumulation of EC-SOD has a direct effect on preventing MMP activation 
in the airspace.  However, the studies in EC-SOD knockout mice also did not reveal additional 
MMP activation in the BAL fluid, indicating that airspace EC-SOD has negligible effects on 
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MMPs in that location.  While simultaneous alterations of EC-SOD and MMPs do not prove an 
association between the two proteins, it does suggest that they may be related in regulation. 
To more directly test the role of EC-SOD in MMP activation, pulmonary fibrosis was 
induced in EC-SOD knockout mice.  In the asbestos model, although MMPs were always 
increased after exposure, we did not find any differences in MMP-2 and MMP-9 when knockout 
mice were compared to wild type mice at 1, 14, and 28 days in either the BAL fluid or lung 
homogenates (Figure 46 and Figure 47).   
The bleomycin model also revealed largely negative effects of EC-SOD on MMPs.  
However, at 24 hours after bleomycin injury, a significant increase was found in BAL fluid 
MMP-9 in knockouts versus wild types at 24 hours (Figure 49).  This increase was associated 
with a significant increase in PMNs in the knockout mice over the wild type mice that was not 
present at later timepoints, suggesting that these PMNs are the source of the MMP-9 (Figure 50).  
Overall, we found that EC-SOD does not have a direct effect on MMP activation but can have a 
modulatory role on inflammation that leads to differential MMP expression. 
 To examine the converse question of whether MMPs play a role in EC-SOD localization, 
we treated wild type mice with asbestos and a global MMP inhibitor, GM6001.  Treatment with 
this inhibitor reduced asbestos disease severity, including a decrease in neutrophil influx and 
fibrosis (Figure 40 and Figure 41).  In addition levels of airspace EC-SOD were reduced, 
suggesting that airspace EC-SOD is regulated by MMPs, likely due to the influx of PMNs.   
 The data presented above indicate a central role for inflammation in the regulation of 
both EC-SOD and MMPs in pulmonary fibrosis.  When EC-SOD is absent from the lungs, 
greater inflammation is observed after challenge.  These findings not only apply to our models of 
pulmonary fibrosis, but to other pulmonary injuries such as hyperoxia, oil fly ash, LPS-induced, 
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and hemorrhage induced lung damage (197, 199, 201, 286).  It has been proposed that these 
increases in inflammation are related to effects on TNF-α and vascular endothelial selectins, two 
factors critical to leukocyte infiltration into the lung.  In the bleomycin model, an increase in 
MMP-9 is found at 24 hours in knockout mice compared to bleomycin- or saline-treated wild 
type mice.  Since MMP-9 can be released from PMNs (274), it is likely that these cells are 
releasing MMP-9 into the airspace.  Therefore EC-SOD can decrease levels of MMP-9 in the 
lung by antagonizing influx of PMNs.   
 It is unexpected that the asbestos model does not follow the same pattern as the 
bleomycin model.  No increases in MMP-9 are noted at 1 or 28 days in the airspaces of EC-SOD 
knockout mice in spite of increases in PMN at these timepoints compared to wild type mice.  It is 
possible that the bleomycin effect is an acute one, and that increased MMP-9 appears earlier in 
asbestos injury at a timepoint before 24 hours.  Also, the bleomycin experiment in EC-SOD 
knockouts showed only a small increase in MMP-9 activity at a time (1 day) when the wild type 
mice had no MMP-9 at all.  In the asbestos model, there is a large amount of MMP-9 in both 
wild type and EC-SOD knockout mice after exposure.  A small increase in MMP-9 might be 
obscured by the larger overall increases observed.   
 The higher level of MMP-9 in EC-SOD knockout mice could indicate a role for MMP-9 
in the greater inflammation and fibrosis observed in these mice.  MMP-9 could be used by the 
inflammatory cells in migration into the lung.  Our studies showing that MMP inhibition reduces 
inflammation support this idea.  Although studies by Betsuyaku et al., shows that MMP-9 null 
mice are not protected from bleomycin-induced pulmonary fibrosis (219), it is possible that other 
MMPs compensate for loss of MMP-9.  The role of MMP-9 as either a contributor or bystander 
to lung injury remains to be determined.    
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 Inflammation also appears to play a role in EC-SOD localization, as MMP inhibition 
reduces both inflammation and EC-SOD accumulation in the BAL fluid.  Our results from 
Chapter 6 showed that inflammatory cells are a major source of this antioxidant in the airspaces 
in pulmonary fibrosis.  Other investigators have also indicated that inflammatory cells can 
produce EC-SOD (184).  The significance of this loss of EC-SOD from the airspaces is unclear 
since mice given the MMP inhibitor are protected from disease.  Although we had proposed that 
airspace EC-SOD is protective against inflammation-induced lung damage, it is possible that 
airspace EC-SOD is pathogenic by a function not previously described.  In all likelihood 
however, decreases in airspace EC-SOD after MMP inhibition simply reflects the fact that fewer 
leukocytes are in the airspace to release it.  Protection may be achieved from overall reduction in 
inflammation.  Nevertheless, these results indicate that EC-SOD localization can be influenced 
by MMP inhibition indirectly through modulation of inflammation.   
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11. DISCUSSION AND FUTURE DIRECTIONS 
Idiopathic pulmonary fibrosis and asbestosis are debilitating lung diseases characterized by a 
progressive disease course and poor prognosis.  The only known cure for these diseases is lung 
transplantation, a treatment limited by the availability of donated organs and the complications 
inherent in organ transplantation.  Enhanced understanding of the pathogenesis of this disease 
would aid in the development of more conventional therapies for pulmonary fibrosis.  Based on 
evidence in humans and in experimental models, it is thought that both oxidant/antioxidant and 
protease/antiprotease imbalances are critical to the development of pulmonary fibrosis.  In our 
study, we examined the regulation of the EC-SOD antioxidant and the matrix metalloproteinases 
in animal models of pulmonary fibrosis.  EC-SOD is abundant in the lung and is known to be 
protective in a variety of lung injury models.  It localizes to the extracellular matrices of the lung 
due to the presence of a heparin-binding domain that confers affinity for the matrix.  Clearance 
of EC-SOD from the lung parenchyma has been observed in disease states, likely due to cleavage 
of this domain.  While the in vivo protease responsible for this event in pulmonary fibrosis is 
unknown, it is known that members of the MMP family of proteases are upregulated in the 
disease process and could therefore contribute to this regulation of EC-SOD.   
It was hypothesized that depletion of EC-SOD from the lung and interrelated increases in 
MMP activity contribute to the development of pulmonary fibrosis.  To examine this hypothesis, 
an asbestos model was characterized that closely resembled human IPF histopathologically. We 
found that EC-SOD is depleted from the lung parenchyma and accumulates in the airspaces after 
induction of lung injury in this model.  MMPs were increased in both lung parenchyma and 
airspaces in response to asbestos.  Our studies also determined that the presence of inflammation 
could in part explain these alterations in EC-SOD localization and MMP activity.   
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 Figure 52.  Model for regulation of EC-SOD in lung in pulmonary fibrosis. 
The normal lung (top) has intact vascular endothelium and alveolar epithelium.  EC-SOD with its heparin-
binding domains sticks to the extracellular matrix of the lung parenchyma (interstitium) and protects the 
lung from oxidative stress.  Inflammatory cells are not present in the lung but circulate in the bloodstream. 
In pulmonary fibrosis (bottom), endothelial and epithelial permeability increases and the interstitium 
expands due to edema or fibrosis.  Inflammatory cells emigrate into the parenchyma, releasing proteases and 
ROS.  Resident macrophages, epithelium, and fibroblasts can also release proteases and ROS.  The heparin-
binding domain of EC-SOD is cleaved, and EC-SOD either diffuses into the plasma or is proteolyzed, 
increasing susceptibility of the lung parenchyma to oxidative stress and potentially leading to propagation of 
inflammation.  It was also shown that EC-SOD expression is decreased after asbestos, which may further 
contribute to decreased lung parenchymal levels.  Inflammatory cells that have reached the airspaces release 
EC-SOD into the alveolar lining fluid which could help to prevent further inflammation.   
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11.1. EC-SOD LOCALIZATION IN ASBESTOSIS 
These studies first characterized an asbestos-induced model of pulmonary fibrosis that more 
closely simulates the development of asbestosis and IPF than the more common bleomycin 
method.  In this model, airspace and interstitial inflammation progressed to interstitial fibrosis.  
We found that EC-SOD was depleted from the lung parenchyma in a sustained fashion 
throughout the inflammatory and fibrotic phases of the disease.  Concurrently, EC-SOD 
accumulated in the BAL fluid.  Although the origin of the airspace EC-SOD was unknown, our 
findings initially suggested that EC-SOD that was removed from the lung parenchyma 
redistributes into the airspaces.   
In order to determine the source of this EC-SOD, experiments were performed in a model 
of airspace inflammation that is not complicated by the presence of interstitial inflammation or 
matrix remodeling.  It was observed in this bacterial model that EC-SOD accumulated in the 
airspaces in the absence of depletion from the lung parenchyma.  These studies revealed that 
airspace EC-SOD is likely due to the airspace inflammation and not the redistribution from the 
lung parenchyma.  This was confirmed by the presence of only mouse EC-SOD in the airspaces 
of asbestos-treated transgenic mice expressing the human form of EC-SOD in the lung.  This is a 
major advance in the understanding of the regulation of EC-SOD in lung disease as it has not 
been previously demonstrated that inflammation is responsible for transport and release of EC-
SOD in the lung airspaces.  In addition, this model demonstrated that interstitial processes such 
as inflammation and matrix remodeling are responsible for the clearance of EC-SOD from the 
lung parenchyma.  These processes are unique to pulmonary fibrosis and cannot be recapitulated 
with airspace inflammation alone.  Our overall understanding of the regulation of EC-SOD in 
pulmonary fibrosis is modeled in Figure 52. 
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11.1.1. EC-SOD depletion from the lung parenchyma 
Proteolytic cleavage and decreased mRNA expression is likely responsible for the depletion of 
EC-SOD from the lung parenchyma.  The heparin-binding domain is unique to this isoform of 
SOD and is particularly sensitive to cleavage by a number of proteases (176).  It has been shown 
that the half-life of EC-SOD in tissues dramatically decreases when its heparin-binding domain 
is cut (287).  Decreased expression of EC-SOD has not been previously demonstrated in 
interstitial lung injuries, indicating that asbestos has unique effects on the expression of this 
antioxidant. 
Loss of EC-SOD should increase oxidative stress in the lung parenchyma as EC-SOD is the 
major extracellular antioxidant enzyme in the lung.  The functional consequence of this may be 
to contribute to the progression of the disease.  Indeed, when EC-SOD knockout mice were 
challenged with asbestos, they developed worse inflammation and fibrosis compared to similarly 
treated wild type mice.  This mechanism of increased oxidative stress through removal of EC-
SOD from the lung parenchyma demonstrates the importance of antioxidant protection in 
pulmonary fibrosis and suggests that antioxidants may be viable treatment modalities for patients 
with IPF.   
11.1.1.1. Future Directions: Protease Inhibition 
 
  Since EC-SOD is protective in asbestos- and bleomycin-induced lung injury, methods by 
which to facilitate retention of EC-SOD in the matrix may be therapeutic.  As proteolytic 
removal of the heparin-binding domain is the most likely mechanism for EC-SOD clearance 
from tissues, protease inhibition may be an effective method to achieve this goal.  Experiments 
aimed at determining which protease or proteases are cleaving EC-SOD in vivo are currently 
being performed.  Unfortunately, the positively-charged heparin-binding domain is particularly 
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sensitive to cleavage and has been shown to be cut by many different classes of proteases in 
vitro.  Therefore, protease inhibition in vivo will have to target numerous proteases in order to be 
successful.  Dichloroisocoumarin, E-64, and GM6001 or 1,10-phenanthroline as inhibitors of the 
serine, cysteine, and metallo-proteases, respectively, are being tested in conjunction with 
asbestos treatment in mice.  Prevention of EC-SOD removal from the lung with any of these 
inhibitors would indicate that a particular class of proteases contains the enzyme responsible for 
proteolysis.  More specific inhibitors can then be applied in these experiments.  Unfortunately, it 
should be noted that complete protease inhibition can be difficult to achieve in vivo.  Negative 
results could either mean that the proteases inhibited play no role in the endpoint being 
examined, or that the inhibitor was not delivered at the optimal concentration or cannot gain 
access to the correct location.  Furthermore, toxicity of the inhibitors complicates these 
experiments as many proteases are involved in normal homeostatic processes such as 
coagulation.  Depending on the target protease, the side effects of inhibition will likely decrease 
as more specific inhibitors are utilized.   
To circumvent problems with pharmacologic inhibition of proteases, we are also 
assessing EC-SOD clearance in mice that are knockouts for various proteases.  In collaboration 
with Dr. Wendy Mars, we have already examined this question in mice that do not express 
plasminogen (the precursor to plasmin), urokinase plasminogen activator, and tissue 
plasminogen activator.  MMP-9 knockout mice have also been examined.  So far, no single 
knockout mouse has been shown to prevent the loss of EC-SOD during the development of 
pulmonary fibrosis.  These studies are continuing with mice that are null for MMP-7, an 
important MMP that is upregulated highly in IPF.  This MMP can cleave syndecans in the 
extracellular matrix.  Syndecans bind to heparan sulfate, to which full-length EC-SOD can 
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adhere.  MMP-7 may cut syndecans in the extracellular matrix, leading to clearance of the 
syndecans and associated EC-SOD from the lung parenchyma.  Furthermore, MMP-7 could 
directly proteolyze the heparin-binding domain of EC-SOD or could facilitate cleavage by 
another protease through release of syndecans from the matrix.   
 
11.1.1.2. Future Directions: Effects of EC-SOD on inflammation in asbestosis 
 
The mechanisms of EC-SOD’s modulation of inflammation are not completely understood.  
One investigation found that EC-SOD is related to the expression of TNF-alpha and endothelial 
selectins after LPS-injury in the lung (201).  Additional studies of other cytokines such as IL-1 
and IL-6 and chemokines such as KC (IL-8 in humans) and their changes in response to loss of 
EC-SOD are warranted.   
It is also known that type I collagen can be fragmented by exposure to reactive oxygen 
species (277).  EC-SOD has been shown to co-localize with type I collagen in the lung (172).  It 
has been demonstrated that EC-SOD can directly bind to and protect collagen from oxidative 
fragmentation in vitro (174), and EC-SOD knockout mice have increased levels of oxidative 
collagen fragmentation in the lung in vivo (204).  Collagen fragments can be chemoattractants 
and activators of PMNs (205, 206).  Examination of oxidative fragmentation of collagen through 
measurement of oxidized proline residues by HPLC will be performed in our asbestos model.  
Higher levels would indicate a potential role in PMN chemotaxis.  The role of collagen 
fragments in vivo would be tested with commercially available antibodies that block PMN cell 
surface receptors for collagen, such as β1 integrins or discoidin domain receptor 1 (288, 289).  
Preliminary data in our lab shows that these antibodies block PMN chemotaxis to oxidized 
collagen in vitro. 
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11.1.2. EC-SOD accumulation in airspaces 
Our data in the pneumonia model revealed that accumulation of EC-SOD in the BAL fluid was 
not due to clearance from the lung parenchyma.  Rather, this EC-SOD originated from the 
inflammatory cells infiltrating the airspaces.  This finding was confirmed by the examination of 
airspace protein accumulation in mice that have lung-specific expression of human EC-SOD.  
After asbestos exposure, the EC-SOD present in the BAL fluid was the mouse isoform, 
indicating an extrapulmonary source (i.e. inflammatory cells) of EC-SOD.   The purpose for 
release of EC-SOD from inflammatory cells is currently unknown.  It is hypothesized that EC-
SOD is anti-inflammatory as EC-SOD knockout mice develop worse inflammation in the lung 
while EC-SOD transgenic overexpressors exhibit attenuated inflammation after challenge.  
Release of EC-SOD by leukocytes may act as molecular brakes to limit further influx of PMNs. 
These studies also show that EC-SOD can prevent increases in MMP levels in the lung.  It is also 
possible that EC-SOD release compensates for the large amount of ROS released from activated 
inflammatory cells.  EC-SOD may prevent inadvertent damage to the lung while still allowing 
for immunological defense utilizing ROS.   
 
11.1.2.1. Future Directions: Neutrophil and Macrophage Depletion 
To test further which inflammatory cells are releasing EC-SOD in this disease, selective 
depletion of leukocyte subtypes will be performed.  PMNs and macrophages are two sources of 
EC-SOD that are being investigated.  Since PMNs are present in much higher levels in 
asbestosis, current experiments are aimed at depleting these cells first.  PMNs can be depleted 
through use of an anti-neutrophil antibody that causes complement-mediated lysis and has been 
used successfully in a hyperoxic lung injury model (197).  This antibody is currently being tested 
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in our own asbestos model to determine effects on EC-SOD airspace accumulation.  If PMN 
depletion does not reduce EC-SOD in the BAL fluid, alveolar macrophage depletion will be 
attempted with clodronate (290).     
To test the functional relevance of this leukocyte-derived EC-SOD, an experiment is being 
designed to examine the inflammatory response in mice whose leukocytes do not possess EC-
SOD.  Wild type mice will be irradiated to ablate their bone marrow and prevent granulopoiesis.  
These mice will then receive bone marrow transplants from EC-SOD knockout donors.  The 
leukocytes derived from this transplanted bone marrow will not have the ability to produce EC-
SOD.  It is hypothesized that the resulting inflammatory response induced by asbestos will be 
greater than that produced by control mice with wild type bone marrow transplants.  
Furthermore, it is expected that greater damage will occur to airspace components because of 
loss of the protective EC-SOD released from the inflammatory cells.  Markers of oxidative stress 
in proteins (carbonyl modifications and nitrotyrosine) and lipids (TBARS) will be assessed to 
determine this.  These experiments will help to determine why leukocytes carry and release EC-
SOD in sites of active inflammation.  Other bone marrow stem cells from the EC-SOD knockout 
mice may also have an effect on the disease process.  While this is a confounder to the 
inflammation studies, it also presents an opportunity to determine whether EC-SOD has a role in 
these stem cells as well. 
Depletion of leukocytes also provides an opportunity to determine disease progression in 
the relative absence of inflammation.  These cells can produce a number of pathogenic 
mediators, such as ROS, proteases, and proinflammatory cytokines and chemokines to attract 
even more inflammatory cells and fibroblasts.  Furthermore, our studies have not ruled out that 
interstitial inflammation (not airspace inflammation) is responsible for the proteolytic removal of 
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EC-SOD from lung parenchyma.  This hypothesis can be directly examined in experiments with 
PMN-depleted mice.  Eliminating or reducing these cells may confer a protective benefit against 
development of disease through any or all of these mechanisms.   
However, a recent report also shows that leukocytes can downregulate the immune 
response.  When alveolar macrophages were depleted before LPS challenge in rats, PMN 
recruitment was increased by 320% (290).  This indicates that these macrophages have an 
important role for downregulating immune responses in the lung.  Importantly, we have observed 
that macrophage numbers are markedly decreased in response to crocidolite asbestos (Figure 7 
and Figure 40).  Depletion of these cells may promote the development of PMN inflammation. 
 
11.2. MMP UPREGULATION IN ASBESTOSIS 
These studies revealed that MMP-2 and MMP-9 are increased after asbestos exposure in mice.  
MMP inhibition was also able to ameliorate the development of fibrosis and inflammation.  An 
exhaustive literature search did not reveal any previously published reports reporting an increase 
in MMP-2 and MMP-9 in asbestos-related fibrotic lung disease in humans or animals.  
Furthermore, MMP inhibition has not been examined previously in this disease. Overall it 
appears that MMPs do play a pathogenic role in the development of asbestosis.   
 
11.2.1. Consequences of increased MMP-2 and MMP-9  
 Although their substrate specificity for type IV collagen would suggest a role in 
basement membrane degredation, these MMPs have multiple substrates and potential roles that 
remain to be evaluated in the context of asbestosis.  Basement membrane degredation may 
enable inflammatory cells and fibroblasts, two of the major effectors of asbestos-induced lung 
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injury, to migrate into the lung.  In the case of inflammation, greater numbers of leukocytes 
could initiate damage through their elaboration of proteases and ROS.  Fibroblast migration, on 
the other hand, would lead to the extensive fibrosis characteristic of the disease.  The degredation 
of basement membrane could also contribute to fibrogenesis through impaired 
reepithelialization.   
 
11.2.1.1. Future Directions: in situ zymography 
 
Another important step in the studies of these MMPs is to examine their activity in the 
tissues.  Although MMP-2 and MMP-9 were observed to be upregulated by zymographic 
analysis, the TIMPs were also increased.  Whether these TIMPs are playing any role in 
inactivating the MMPs will be determined through in situ zymographic analysis.  This technique 
localizes active gelatinase activity in histological sections of tissue.  If these MMPs are being 
inhibited by TIMPs, they will not be detectable.  This technique therefore allows for the 
determination of levels of activity in the tissue itself. 
 
11.2.1.2. Future Directions: MMP-9 knockout experiments 
 
While it has been shown that MMP-9 null mice do not have a significant phenotype 
change in response to bleomycin (219), compensation by other MMPs was not examined and this 
does not rule out a role for MMP-9 in asbestosis.  MMP-9 knockout mice are currently being 
examined to determine their role in asbestos-induced pulmonary fibrosis, testing the hypothesis 
that these mice will be protected from disease progression.  If protection is found, the 
mechanisms by which this benefit is mediated will be examined.  Apart from its collagen-
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degrading capabilities, MMP-9 can also inactivate alpha-1-proteinase inhibitor and cleave IL-1β.  
These proteins can be assayed by activity assay and ELISA, respectively.  Alpha-1-proteinase 
inhibitor is already known to play a role in emphysema and has been postulated to play a role in 
pulmonary fibrosis.  It is also known for its sensitivity to oxidative inactivation, perhaps 
indicating a target of converging pathways involving both EC-SOD and MMPs.  IL-1β is a 
proinflammatory cytokine capable of promote development of pulmonary fibrosis.  The MMP-9 
knockout will allow us to determine whether MMP-9 plays a role in the activity of these 
proteins.   
 
11.2.1.3. Future Directions: MMP-7 knockout mice 
MMP-7 (matrilysin) was shown to have a surprising role in the development of bleomycin-
induced pulmonary fibrosis as well as in human IPF.  This MMP has not yet been studied in 
asbestosis.  MMP-7 null mice are now being bred in the animal facility and the role of MMP-7 in 
development of inflammation and fibrosis will be assessed.  We hypothesize that the knockout 
mice will be protected against the development of fibrosis.  It has been shown that MMP-7 
cleaves syndecan, upon which a neutrophil chemoattractant, KC, is bound.  KC is the murine 
homologue of human IL-8.  This cleavage helps to set up a chemotactic gradient for the 
neutrophil in response to KC in bleomycin-induced lung injury.  The same mechanism will be 
examined in asbestosis, as well as measure endpoints such as inflammation and fibrosis.  
Ongoing studies in our laboratory have failed to identify the same increases in MMP-7 in 
asbestosis as is seen in the bleomycin model.  While this may be due to the low levels of MMP-7 
transcripts in the lung, it could also indicate that MMP-7 does not play a role in asbestosis.  This 
discovery would indicate that there are differences between asbestosis from IPF despite their 
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histologic similarities and suggest that different mechanisms may contribute to the pathogenesis 
of these diseases.    
 
11.3. INFLAMMATION IN THE REGULATION OF EC-SOD AND MMPS 
These results indicate that EC-SOD can modulate levels of MMPs through effects on 
inflammation.  Increased inflammation led to greater MMP-9 levels in the BAL fluid.  
Conversely, MMP inhibition also had inhibitory effects on lung inflammation, and this played a 
role in the accumulation of EC-SOD in the airspaces.  The implications and future directions 
related to increased MMPs and EC-SOD were already discussed above.  These studies for the 
first time show that EC-SOD and MMPs may regulate each other in the lung through effects on 
inflammation.  These findings increase our understanding of the interrelationships and convering 
pathways due to oxidant/antioxidant imbalances and protease/antiprotease imbalances in diseases 
of the lung.  
  
11.4. CLINICAL IMPLICATIONS 
The discovery of potential involvement of EC-SOD and MMPs in the development of asbestosis 
and pulmonary fibrosis in general suggests a number of clinical implications for therapy.  The 
finding of decreased EC-SOD in lung parenchyma supports the continued research into N-
acetylcysteine and other antioxidants as treatments for the disease.  Similarly MMP inhibition 
can have a protective effect by inhibiting the development of fibrosis.  While it is true that the 
experimental results with MMP inhibition were observed when inhibition was given before the 
addition of asbestos, this study is not irrelevant for a human disease in which patients present 
with the disease already in development.  IPF is a relentlessly progressive disease.  MMP 
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inhibition could slow the progression of the disease by slowing the development of new fibrosis.  
In the same way, antioxidant therapies would prevent progression after a patient has presented.  
Since asbestos involves continued production of ROS from iron-laden asbestos fibers over the 
course of the disease, this type of therapy may be even more beneficial in the setting of asbestos 
fibers.  In any event, it is critical that the molecular mechanisms of pulmonary fibrosis be more 
fully understood so that rational decisions about experimental therapies can be made.  It is hoped 
that the research described in this thesis can contribute to this understanding so that future 
studies will have a firm foundation upon which to develop novel therapies for pulmonary fibrosis 
and other lung diseases.   
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